

Antibiotice S.A. on September 30, 2025

Investments

Antibiotice SA is implementing an ambitious, multi-annual investment plan funded through both internal resources and external funds, aiming to strengthen research, production, and innovation capabilities.

- Between 2025 and 2029, Antibiotice SA is executing a recently approved investment totaling 375 million lei, partially (52%) financed by the Health Program. This investment focuses on developing the modern R&D center "INOVA a+" and constructing a new production capacity for critical medicines (sterile injectable powders).
- Simultaneously, from 2023 to 2029, the company is carrying out investments approved through a state aid granted by the Ministry of Finance (InvestEU), amounting to 250 million lei. Of the three project objectives, the finished products warehouse has already been completed, while the flow for sterile topical products and production capacity for sterile injectables are in the equipment procurement and design stages.
- Additionally, Antibiotice SA continues to invest in research and development projects for new medicines, license acquisitions, digitalization, as well as modernization of production units and laboratory equipment for quality control and assurance. In the first nine months of 2025, these investments totaled 47.26 million lei.

External Market

On the international market, export revenues reached 202.6 million lei, similar to 2024, reflecting the stability of the external portfolio and the strategic importance of international markets, which contribute 38% to the total turnover. Finished product exports increased by 3%, reaching 133.4 million lei. Over the past five years, exports have risen by 66%, now accounting for 38% of total turnover. Europe remains the primary market for finished products, with strong sales both in established markets (UK, Nordic countries, Hungary, Serbia, Baltic States) and new markets (Italy, France, Poland, Czechia, Bulgaria), while Asia-Pacific and America

account for 48% of international turnover. Export development relies on sustainable strategic partnerships and medium-term contracts, including new projects recently implemented in Germany, Spain, and Turkey. Steady growth has been observed across all regions, and estimates for the year's end indicate sales will surpass planned figures by over 5%.

In the active substances domain, Nystatin continues to reinforce Antibiotice's position as a global leader, maintaining a stable presence in Europe, Asia, and North America, with significant progress in development projects in North and Latin America, thereby strengthening its foundation for future international expansion. The company exports this active substance to over 50 countries worldwide.

The outlook for the coming years remains positive, supported by growth strategies based on strategic partnerships, expansion into new markets, and strengthening its global presence.

Domestic Market

On the domestic market, revenues totaled 265.3 million lei, representing a 12.5% decline amid an economic context marked by high inflation, reduced purchasing power, and adjustments in medicine consumption, along with announced fiscal measures and changes in patient consumption behavior.

Despite this, Antibiotice maintains leadership in key pharmaceutical segments:

- 4th position in consumption (out of 372 companies) among manufacturers of prescription and over-the-counter generic medicines in Romania (4.8% market share);
- Leader by value in hospitals (13.6% market share in the prescription and non-prescription generic medicines segment) in a market with 248 active companies;
- Leader by quantity in pharmaceutical forms such as ointments (19.6% of 131 companies), suppositories and ovules (32.4% of 53 companies), injectable powders (59.8% of 60 companies);
- First position in the oral anti-infectives market (22.7% market share among 45 companies).

Over the past five years, domestic market revenues have risen by 80%, now accounting for 62% of total turnover.

Despite economic challenges, Antibiotice SA consolidates its position as a strategic pharmaceutical company in Romania, demonstrating resilience, adaptability, and consistent performance in its strategic segments.

The year 2025 marks a phase of consolidation and preparation for the implementation of major planned investments, which will support the sustainable development of the company in the following years. The strategy for the upcoming period aims to rebalance territorial sales, intensify commercial partnerships, and capitalize on growth opportunities in both domestic and international markets, in line with the mission to promote health through quality, responsibility, and innovation.

MANAGEMENT REPORT

January - September 2025

Report for the first 9 months according to IFRS

Report Date: 30.09.2025

Name of the trading company: ANTIBIOTICE S.A.

Head Office:

Iasi, 1 Valea Lupului St.

Phone number:

0232/209 000, 0372 065 633

Fiscal registration code:

RO 1973096

Order number in the Trade Register:

J1991000285223

Regulated market on which the issued securities are traded:

Bucharest Stock Exchange

Subscribed and paid up capital:

67,133,804 LEI

Main characteristics of the securities issued by the company:

Nominative shares, nominal value: 0.10 LEI

Contents


Antibiotice – a performance-oriented company	2
Strategic alignment of human resources	3
Modern management of human resources	3
Modernization of organizational culture	4
Strategic alignment of product portfolio	4
Portfolio management	4
Promotional activity	5
Portfolio development through in-house research and development and in-licensing	6
Continuous improvement of integrated management system (Quality, Environment, Occupational Health and Safety)	7
Operational performance	10
Antibiotice in the Romanian market	11
Antibiotice in the international market	12
Management of financial flows and operational expenses	13
Application of business consolidation principles	13
Investments.....	20
Improvement of Corporate Governance systems	21
Risk management	23

Antibiotice - a performance-oriented company

The main results recorded by Antibiotice SA in the first 9 months of 2025:

- total revenues of 498.22 million LEI;
- revenues of 202.6 million lei from sales of finished products and active substances on the international markets, similar to the value recorded in the same period of the previous year;
- ranked 4th by consumption as number of boxes on the the generics market, both prescription and over-the-counter (OTC) in Romania, with a 4.8% market share, according to Cegedim Sell Out Romania - September 2025;
- maintains its position as the value leader in the hospital segment for generic products, both prescription and over-the-counter (OTC), with a 13.6% market share, according to Cegedim Sell Out Romania - September 2025;
- business yield of 17.4% (gross profit including the claw-back tax);
- current liquidity of 4.92 (higher by 1.2 - the reference agreed by the financial institutions);
- the ratio total bank debt/EBITDA of 2.08 (less than 3.5 - the reference agreed by the financial institutions);
- the ratio total bank debt / equity de 0.28 (less than 1 - the reference agreed by the financial institutions);
- the average share price was 2.3158 lei/share.

Shareholder structure as of 30.09.2025



Antibiotice S.A. has been listed on the Bucharest Stock Exchange under the ATB symbol, in the Premium category, since April 16, 1997.

Antibiotice shares are included in the following indices: BET, BET-TR, BET-TRN, BET-XT, BET-XT-TR, BET-XT-TRN, BET Plus, BET-BK.

Market capitalization of Antibiotice S.A. amounted to 1,732,052 thousand lei on September 30, 2025. During the first 9 months of 2025, a number of 39,182,044 shares

were traded, with a total trading value of 90,737,330.44 lei (18,030,689.84 EURO/20,286,805.92 USD) and an average price of 2.3158 lei/share. The ATB share closed the last trading session of the 9-month period at the value of 2.58 lei.

Strategic alignment of human resources

The objectives pursued are: implementation and development of strategies to motivate and retain valuable employees, as well as to attract staff with skills aligned to the pharmaceutical industry, skills aligned with current labor market trends.

Modern management of human resources

In the first 9 months of 2025, *the employee retention rate* was 98.16%, compared to the target of 95% and the rate recorded in the same period in 2024, which was 97.64%. *Implementation of employee training and skills development programs*

The 2025 Annual Training Program for employee skills development organized in collaboration with external suppliers, is part of the *Academy a+* project and is tailored to the requests and evolving training needs identified across departments and employees.

An average of 33 hours of professional training/ employee was scheduled over the first nine months of 2025. An average of 33.5 hours per employee was completed through skills development programs covering areas with mandatory legal training requirements, including sessions with internal instructors, external providers, and via the e-Learning platform.”

Academy A+, as a tool for knowledge management in our company. Academy A+ has two components: Technical College A+ and Business School A+.

Specific actions - collaboration with the academic and pre-university environment was reflected during the first nine months of 2025 through the following initiatives:

- organization of internship programs for 102 students (fields of study: pharmacy, chemistry, electronics engineering, automation engineering, chemical engineering, economics, bioengineering);
- organization of educational visits for 140 students (specializing in pharmacy and economics);
- participation in the ‘Introduction to Career’ event, which included a company presentation and information on employment opportunities for students of the Faculty of Chemical Engineering and Environmental Protection at the “Gheorghe Asachi” Technical University of Iași;
- providing internship programs for 110 students with the qualifications agreed upon in the partnerships signed with technical high schools within the Academy a+ (chemical operators, automation technicians, mechatronics technicians, and laboratory technicians);
- supporting educational activities by organizing study visits attended by 204 students within the “Scoala Altfel” program;
- sponsoring the National Chemistry Olympiad and organizing a visit for 25 Olympiad students.;
- Participation in the evaluation committee for the professional certification of pharmaceutical and cosmetic chemical operators and laboratory chemistry technicians at the “Petru Poni” Technological College Iași;
- Participation in the evaluation of projects for the competition “Director of the Year” - Association for Values in Education;
- Carrying out the two funded projects for student and pupil internships under the Education and Employment Program (PEO), in line with the timelines and milestones established in the contracts. The financing projects were submitted in 2024 and contracted in December 2024 (pupils) and March 2025 (students):

- „Education in Action: Improving the Accessibility and Relevance of Vocational and Technical Education through Internships within Antibiotice S.A.”, with a value of 2,452,958.07 lei, implemented over a period of 36 months, starting on December 1, 2024. This project aims to organize internships for 254 pupils from pre-university, vocational and technical education, facilitating the integration of key skills, including entrepreneurial and digital ones.
- „Antibiotice Skills: Improvements of students’ skills and their adaptation to the labor market”, with a value of 4,857,830.53 lei, funded by the European Social Fund Plus (ESF+), implemented over a period of 24 months, starting on March 1, 2025. Within this project, 251 students will participate in internships in a real work environment within the company.”

Modernization of organizational culture

Programs and activities of a sports, recreational, social, and cultural nature were organized between January - September 2025. Among these, those with significant impact were:

- "Family Day", an event organized on June 24, 2025, which was attended by over 500 people (employees with their families and children);
- the sport event "Trail to the chalet" (14 employees participated in this event), planning prevention and health monitoring campaigns;
- organization of team-building workshop events for various departments within the company;

Strategic alignment of product portfolio

Portfolio management

Product portfolio expansion represents an essential factor in developing the company Antibiotice SA in the domestic and international markets and is achieved both through in-house research and development activities and through strategic business development initiatives.

The criteria considered for portfolio management are:

- market consumption potential;
- therapeutic trends;
- yield per therapeutic unit;
- compatibility with the existing manufacturing workflows.

The products in the current portfolio are closely monitored, with specific actions carried out to ensure alignment with national market requirements and international regulations.

The current portfolio includes 195 products:

- generic medicines for human use from 12 therapeutic classes (prescription medicines (Rx) and over-the-counter medicines (OTC));
- food supplements, cosmetics and medical devices;
- active substances obtained through a biosynthesis process by cultivating the microorganism. *Streptomyces noursei*;
- products for veterinary use (prescription medicines and food supplements);

- biofertilizers.

The prescription medicines portfolio (Rx) is structured into the following therapeutic classes: anti-infectives including the medicines for tuberculosis, cardiovasculars, medicines from the digestive tract and metabolism class, preparations for treating gynecological disorders, dermatologicals and medicines for central nervous system.

The non-prescription portfolio for human use (non-RX) includes OTCs, food supplements, cosmetics and medical devices. These are intended for maintaining health, for prevention, or for use as adjuvants in certain high-incidence conditions, complementing the prescription medicines portfolio.

Portfolio structure by manufacturing divisions	Number of products	Launched in the first 9 months of 2025
Oral Solid Dosage Form	95	9
Topical Products	56	1
Products for Injection	40	
Active Substances	4	

New products

Products launched in 2025: 1 prescription product intended for hormone replacement therapy - Hidrocortizon tablets 10mg, 3 food supplements - Zifelle® meno, intended for women's health during menopause, Urexpert® Prostata, intended for men's health, Soriso® Focus, intended for maintaining cognitive function, 1 topical product Cutaden® Repair, intended as an adjunct therapy for atopic dermatitis, 3 products Almacor Duo intended for the treatment of arterial hypertension and 2 products Ranolazina intended for the symptomatic treatment of patients with stable angina pectoris.

Promotional activity

A. Communication to healthcare professionals (HCPs)

Communication to healthcare professionals is carried out through direct promotional visits and various projects conducted by the medical representatives team, as well as through participation in national congresses and conferences.

Scientific events and activities are organized by the main professional, academic, and scientific societies and associations in Romania. In the reporting period, Antibiotice S.A. attended events focused on the medical specialties of Dermatology, Infectious Diseases including TB, Pulmonology, ENT, Urology, Anesthesiology and Intensive Care, Gynecology, Cardiology, Emergency Medicine, Family Medicine, and Pharmacy, aiming to achieve the following objectives: to enhance the visibility of the company brand and products brands, to launch and promote products, to develop relations with the business partners, to understand the market and competition.

Our company promoted its veterinary portfolio through integrated actions targeting animal health professionals and the general public, including distributor partners, veterinary clinics and pharmacies, breeders, cynology clubs, and pet owners.

Professional communication was strengthened through partnerships with the main professional associations - the Romanian Association of Veterinarians for Companion Animals (AMVAC), the Romanian Society of Veterinary Dermatology (SRDV), the Romanian Society of Feline Medicine (SRMF), and the University of Life Sciences 'Ion Ionescu de la Brad' in Iasi (USV Iasi) - as well as through the organization of regional symposia VetAria+ (Iasi, Bucharest, Cluj, Timisoara).

Visibility of the brand was strengthened by participating in dedicated events (PET EXPO, Animal Fest, Pet Event, Pet Care Fest), digital campaigns and collaborations with influencers in the pet-care sector.

B. Communication to the general public

- Online communication

Social Media - communication projects were carried out with the primary objective of increasing the awareness and visibility of the following brands: Cutaden® range, Tinero® range, Zifelle® meno, Simbiflora®, Soriso®, TriOli®, Urexpert®, Nutriensa®.

Product websites - websites dedicated to the OTCs were launched - Zinba® and Saliform® forte, as well as the food supplement Zifelle® meno. On the Cutaden.ro website a *Blog section* with informative articles was created.

- TV offline communication: Zinba®.
- Radio offline communication for the following brands: Zinba®, Clafen® Rapid, Saliform® Forte, Fluxiv®, Silithor®, Cutaden® bebe, Zifelle® meno, Tri Oli®, Simbiflora, Urexpert®, Faguria®.
- Events for the general public:
 - In the first part of the year, promotional campaigns targeting the general public were carried out for Tinero® AZ range, through healthcare professionals and influencers, to ensure wide exposure tailored to different audience segments. The brands Cutaden bebe, Simbiflora, Faguria and Zifelle® meno were promoted to the general public through participation in high-visibility events, which allowed direct interaction with consumers and communication of the products' benefits in a relevant context.
 - In the reporting period, our company participated in a series of public events dedicated to the veterinary field and pet enthusiasts, bringing together a diverse audience composed of pet owners, veterinarians, manufacturers and suppliers of products and services for animal health and welfare, representatives of institutions with specialized canine units, as well as students and academic staff. The activities included presentations, demonstrations, interactive workshops and professional training sessions, with the main objectives of increasing the visibility of the company's brand and product range VetAria+, developing and diversifying partnerships with veterinarians and strengthening the online community.

These actions contributed to increasing brand visibility and strengthening the relationship with the target audience.

Portfolio development

The product portfolio is developed in accordance with the directions set in the "The Future Together 2030" business plan.

The integration of new products into the company's portfolio is achieved both through research and development projects conducted within the in-house INOVA a+ center, as well as through the acquisition of licenses for products we wish to include in our portfolio but which are not compatible with existing manufacturing processes in terms of pharmaceutical dosage forms, product classes and packaging method.

For 2025, the INOVA a+ research center has planned research stages for 54 projects. Complexity of the process of creating a new product in accordance with international regulations applicable to the pharmaceutical field gives research and development projects a multi-year character.

Thus, out of the total research projects planned in 2025, a number of 38 projects have been running since 2024.

The distribution of research projects for 2025, by divisions, is as follows:

- *Topical Products Division - 28 projects.*
- *Oral Solid Dosage Forms Division - 11 projects.*
- *Sterile Injectable Products Division - 15 projects.*

In the first 9 months of 2025, the INOVA a+ Center carried out various stages for 45 projects, Rx products (medical prescription medicines) and non-Rx products (OTCs, food supplements, medical devices and dermatocosmetics):

- *Topical Products Division - stages for 22 projects;*
- *Oral Solid Dosage Forms Division - stages for 8 projects.*
- *Sterile Injectable Products Division - stages for 15 projects.*

In the first 9 months of the year, 7 projects research projects were successfully completed and have been handed over to the department responsible for obtaining marketing authorizations, in accordance with applicable regulations.

Through the in-licensing, our company contracted 11 products, of which 4 medicinal products for human use intended for the treatment of cardiovascular disorders, and 7 veterinary products intended for the treatment of metabolic and musculoskeletal disorders.

These products for veterinary use are expected to generate sales starting from 2026, while the products for human use are expected to generate sales starting from 2029.

With respect to the activity conducted during the first nine months of 2025 within the Clinical Studies Center, progress was made on three clinical studies, two of which were successfully completed. The results obtained constitute a mandatory component of the marketing authorization documentation and provide a significant advantage in communicating product benefits of the Antibiotice products to healthcare professionals.

Continuous improvement of the integrated management system (Quality, Environment, Occupational Health and Safety)

Ensuring product quality, reducing quality incidents, incidents of any nature with repercussions on human health and environment represent the main ethical, moral and professional concern in our company.

In the perspective of continuous strategic development, Antibiotice is permanently concerned with improving its processes and aligning with the constantly changing legislation. In this regard, during 2025, from a quality point of view, the following inspections for authorization, major changes and GLP/GMP certification took place:

- on 28.01.2025, the NAMMDR recertification inspection regarding Good Laboratory Practice (GLP) took place at the Clinical Studies Center;
- on 29.01.2025, an authorization inspection by ANMDMR of the new finished product warehouse took place;
- on 06.02.2025 the NAMMDR conducted an inspection for authorizing the installation of the Restricted Access Barrier (RABS) system on the existing manufacturing lines in the Parenteral Products Site with the aim of aligning with the requirements of Annex 1 (revised) of the Good Manufacturing Practice (GMP) guidelines;
- on 09.05.2025, the NAMMDR conducted an inspection for authorizing the second microbiological analysis laboratory (Determination of microbiological activity);
- in the period 15-19.09.2025, the NAMMDR conducted a recertification inspection on Good Manufacturing Practice (GMP): for
 - all human medicinal products and clinical trial drug manufacturing lines within the company, including partial manufacturing (secondary packaging), along with all utilities associated with each line;

- manufacturing flow for the active substance Nystatin;
- laboratories for testing the medicines in view of their release to the market;
- warehouses for raw materials, packaging materials and finished products;
- import flows of medicinal products and intermediates from third countries

Furthermore, in the first nine months of 2025, three audits were conducted by partners for contract manufacturing of parenteral products. The audits were successfully completed, Antibiotice furthering the partnerships established.

With reference to the periodic training on specific GMP topics, on the internal component, this training took place according to the approved Annual Training Plan, and on the external component, the members of the Quality Assurance Department participated in 5 workshops conducted by external suppliers addressing current topics specific to the pharmaceutical industry.

Environmental responsibility

Between January - September 2025, Antibiotice S.A. carried out its activity in full compliance with legal requirements and regulations in force regarding environmental protection, continuing to implement the commitments assumed through the sustainability and integrated management policy.

Compliance with environmental regulations

The environmental permits were maintained in force:

- Integrated Environmental Authorization no. 3/29.09.2021, issued by the Iasi Environmental Protection Agency;
- Water Management Authorization no.20/30.03.2021, issued by the Prut-Barlad Water Basin Administration.

On 23.01.2025, officials from the Prut-Barlad River Basin Administration - Romanian Waters Iasi carried out a technical inspection. No non-conformities were identified.

The drilling works for the wells within the project "Reducing potable water consumption by using groundwater for water treatment/irrigation" (Decision of the classification stage no. 55 of 03.04.2023) were completed, and the *Technical Book of the groundwater abstraction* was prepared, in accordance with Annex No. 4, Section 3, Art. 9 of the Order of the Ministry of Environment and Waters Administration no. 3147/2023. As a result, the Water Management Authorization no. 72/ 09.09.2025 for modifying waters was obtained, the procedure being completed. The required documentation was prepared and sent according to legal requirements, with all related administrative steps completed on schedule.

Following the field visit (September 04, 2025) conducted by the representatives of the Iasi County Environmental Protection Directorate, the Annual Approval of the Integrated Environmental Authorization was granted, through Decision no. 668/12.09.2025.

The notification regarding the project "Green Park development" was sent to the Iasi County Environment Directorate, finalized with Decision no. 4497/27.08.2025 - the works do not fall under the procedure according to Law no. 292/2018 regarding environmental impact assessment. The project is ongoing, and the works are currently in progress."

Transparency and reporting

The company ensured the fulfillment of all reporting obligations stipulated in the regulatory documents, transmitting information to the competent institutions (APM Iasi, ABA Prut-Barlad).

Also, the Annual Environmental Report for 2024 was prepared and published on the company's website, according to the requirements of the Integrated Environmental Authorization.

In the period June 25 - 28, 2025, Antibiotice SA organized the "Open Day" event, an initiative aimed at facilitating an open and constructive dialogue, offering community members the opportunity to become familiar with the company's activities and projects.

This initiative aimed to strengthen the relationships with stakeholders, local authorities and citizens from the Iași County and from the localities Valea Lupului, Reditu, Uricani și Miroslava, and to underline the commitment of Antibiotice SA to sustainable development, public health, and environmental protection.

After a three-year pause, the event returned with remarkable community interest – over 250 visitors joined the guided tours on the Antibiotice site.

Structuring the visits by segments allowed for personalized and effective communication with each participant category, contributing to the strengthening of trust and cooperation between the company and the community.

Through this initiative, Antibiotice reaffirms its commitment to open dialogue with stakeholders and to the principles of social responsibility and sustainability that guide its activities.

Resource management and environmental protection

Periodic monitoring of the quality of environmental factors was carried out as follows:

- Water analyses were performed in our own laboratory and in third-party laboratories to control the quality of water introduced into the pre-treatment plant and discharged into the municipal sewage system;
- Determinations regarding air emissions were carried out in accordance with the requirements of the integrated authorization.

No exceedances of the established limit values were recorded.

Sustainable waste management

Antibiotice continues to implement an efficient and sustainable waste management system, based on the principles of selective collection, recovery and traceability.

- The internal audit on waste management for 2024 was completed;
- Waste is separately collected and sent to authorized operators for utilization or final disposal, with certain types being incinerated on-site;
- The company implemented the *Waste Prevention and Reduction Program*, and the document is available on its official website for reference.
- On 03.04.2025, a second-party audit was conducted at the incineration disposal service provider, targeting waste traceability and compliance with ISO 14001, ISO 9001, and legal and contractual requirements. Auditul a fost finalizat fara identificarea unor neconformitati critice care sa genereze riscuri pentru activitatea companiei Antibiotice.
- The Extended Producer Responsibility (EPR) obligations were fulfilled through a contract with an Authorized Organization Implementing the Extended Producer Responsibility (OIREP). The company does not record any outstanding debts to the Environmental Fund Administration.

Climate change and decarbonization

As part of its commitment to reducing its carbon footprint, Antibiotice continued to collaborate with external experts to assess Scope 3 greenhouse gas emissions from its

supply chain and other related activities. Based on these results, the process of developing a Decarbonization Strategy was initiated, aligned with international regulations and climate change objectives.

Occupational health and safety

In order to comply with the legislative provisions regarding the protection of employee health, in the first quarter of 2025, the 2025 Prevention and Protection Plan (revised according to the legislative provisions), the Annual Training Program / Topics for periodic training in the field of Occupational Health and Safety, the Annual Program for periodic medical examination, the Annual Program for monitoring exposure to noxious substances were drawn up.

Technical measures from the Prevention and Protection Plan for 2025 were implemented, which included measures to reduce physical effort.

Periodic training of the staff was carried out according to the Annual Training Program in the field of Occupational Health and Safety (monthly, quarterly, semi-annually) - depending on the specifics of each activity.

The periodic medical check-up was carried out according to the Annual Program for Periodic Medical Examination (100%).

In the first 9 months of 2025, in order to evaluate/improve the health status of the company's personnel, the screening program for 2025 was developed. The first screening stage was prepared (project started in 2024). The first stage of the screening for Vitamin D deficiency assessment was carried out, involving 248 participants, with a new stage planned for Q4."

Monitoring of exposure to noxious substances was carried out according to the Annual Program for Monitoring Exposure to Noxious Substances (100%).

In the first 9 months of 2025, four events were recorded, of which three were work accidents and one minor accident. The affected people recovered their health, and the company's activity was not affected.

Operational performance

During the reported period, total sales revenues were 468.35 million lei, down by 7 % compared to the same period of the previous year (506.05 million lei).

The sales revenues on the domestic market amounted to 265.3 million lei, lower by 12.5% compared to the same period of 2024 (303.2 million lei). In the first 9 months of the reporting year, the inflation rate, according to public data, exceeded 8%, also affecting purchasing power. Therefore, the consumption of medicines was reprioritized within the consumption basket.

Sales revenues on the international market amounted 202.6 million lei, remaining at the same level as the similar period in 2024 (202.3 million lei):

- finished products: 133.4 million lei, up 3% compared to the first nine months of 2024 (129.6 million lei),
- active substances: 70 million lei, down 5% compared to the first nine months of 2024 (74 million lei). The reduction is associated with decreased consumption following the tariff measures announced by the U.S. Our company's strategy is to rebalance the sales through trading policies with our partners.

Antibiotic in the Romanian market¹

In the analyzed period the sale of Antibiotic in the domestic market decreased by 12.5% compared to the similar period of the last year. This is the result of a combination of external and internal factors that negatively affected our commercial performance. The main causes contributing to this outcome are detailed below:

Challenging market conditions

- The domestic pharmaceutical market recorded stagnation in the key segments where the company is active (generic antibiotics, ointments and topical products).
- In the context of economic uncertainties, noticeable changes occurred in consumer behavior, leading to a decrease in demand for products in the company's portfolio. Many patients interrupted or postponed certain therapies, prioritizing urgent medical interventions; this cautious behavior resulted in reduced adherence to prophylactic and maintenance therapies. Furthermore, consumers avoided purchasing over-the-counter products considered non-essential, opting to 'tolerate' minor symptoms rather than invest in preventive treatments.
- The decrease in the incidence of certain conditions – including a reduction in the number of respiratory infection cases as well as other pathologies treated with medicines manufactured by our company – led to lower consumption than forecasted

Legislative and economic pressures

- The announced fiscal measures created uncertainty and anticipation, which influenced patient consumption behavior (reduced pharmacy traffic, lower average transaction value, fewer products per transaction, focus on purchasing chronic treatments).
- Higher inflation and reduced purchasing power directly impacted demand for medicines, especially for certain higher-priced products in the OTC pharmaceutical segment with repeated price increases.
- Reduction of health budgets: The decrease in financial allocations for hospitals had a significant impact on medicine purchases, including on the products from the Antibiotic's portfolio (underfunding of the TB program; hospital tenders result in purchases only if budget lines are approved for each hospital)
- CNAS reimbursements to pharmacies: Delays in invoice payments caused financial instability for pharmacies, which in turn resulted in significantly lower dispensing volumes compared to prior periods.
- The increase in VAT from August 2025 generates a cascading effect throughout the entire value chain—from the manufacturer to the end patient
- Reduced health-related spending by households and a decline in real wages in Romania.

Competitive factors

- Increased competition on the domestic pharmaceutical market: Fierce competition from other companies, especially those offering generic medicines at lower prices, required greater commercial efforts to maintain and stabilize sales. An intensification of promotions and discounts among competitors was observed, especially in the generic segments where we operate (national chains, regional mini-chains).

Contrary to the aforementioned aspects, in the first 9 months of 2025, on the domestic market, Antibiotic:

¹ Data source: Cegedim Sell-Out Romania, January - September 2025

- maintained its fourth rank (out of a total of 372 companies) in terms of consumption - no. of boxes on the segment of generic prescription medicines and non-Rx (4.8% market share);
- leader in terms of value on the segment of generic prescription medicines and non-Rx traded in hospitals, with a 13.6% market share, in a market where 248 companies operate;
- leader in terms of quantity (IU) in the total market for the following pharmaceutical dosage forms: ointments (19.6% out of a total of 131 companies), suppositories and pessaries (32.4% out of a total of 53 companies) and powders for injection (59.8% out of a total of 60 companies);
- ranked first, in terms of quantity as number of boxes in the total anti-infectives market, oral dosage forms (22.7% out of a total of 45 companies).

Antibiotice in the international market

In the first 9 months of 2025, the revenues from the sales of finished products and active substances in the international market amounted to **202.6 million lei**.

The main market in which Antibiotice exported its products: Europe (45%), Asia-Pacific (28%) and America (20%).

As regards the export of finished products, Europe remained the main market, this being part of our company's strategy set in „The Future Together” Business Plan. The growing sales in this area were achieved both in markets where Antibiotice has an established presence (UK, Nordic Countries, Hungary, Serbia, Baltic Countries) as well as on the new markets where our company initiated projects in the last two years (Italy, France, Poland, Czech Republic, Bulgaria).

The development of sales in Europe will continue in the coming years both through the contracts awarded for 2-3 year periods through tenders in the UK, Nordic Countries, Hungary, Italy and through new projects that we are negotiating with partners in Germany, Spain, France, Poland, Holland, etc.

In Q3 2025, three of these new projects were already contracted and implemented in Europe: the distribution of 5 products for injection on the German market (the first delivery was in August), contract manufacturing for the Spanish market for 3 cardiovasculars (the first delivery is scheduled for Q1 2026), respectively the marketing and distribution under VetAria+ brand of the portfolio of food supplements for pets in Turkey (the first delivery was in August).

In the period January-September 2025, we recorded increases in sales of finished products in all the regions (Europe, Asia-Pacific, Middle East, Australia and Africa) compared to planned sales. For the end of the year, we anticipate an increase of over 5% for these regions compared to the level planned at the beginning of the year.

Export of active substances Nystatin, non-micronized and micronized form

The activity carried out in the first half of 2025 followed the trend of recent years and aligned with the strategy to consolidate the company's leadership position on the world market for the stage 2025-2030, the range of the active substance Nystatin Antibiotice, being commercialized in all the major markets globally.

Our company maintained its presence on the main markets (Asia, Europe, North America) and recorded significant progress in the development projects in the North America and Latin America, thus establishing the foundation for the expansion of export markets for this active substance range.

Management of cash flows and operational expenses

Implementation of business consolidation principles

The main diagnostic indicators recorded by 30 September 2025 are summarized in the following table:

Intermediate Management Balances (values are expressed in LEI)

No.	Calculation method	Indicators	30 .09.2025	30.09 2024	30.09 2025/ 30.09.2024
1	1=2+3+4	Revenue from customer contracts (turnover) + Changes in finished goods inventories and work in progress + Revenue from fixed assets projects:	483.591.409	504.157.428	-4%
2		Revenue from customer contracts (net turnover):	468.355.688	506.052.026	-7%
3		Changes in finished goods inventories and work in progress	7.429.099	-10.083.362	-174%
4		Revenue from fixed assets projects	7.806.622	8.188.764	-5%
5		Raw material expenses	101.665.476	93.812.752	8%
6		Material expenses	11.586.763	12.591.283	-8%
7		Expenses on finished products made on partner sites	59.317.539	61.327.743	-3%
8	8=1-5-6-7	Gross margin	311.021.631	336.425.651	-8%
9	9=8/1	Gross margin (%)	64,31%	66,73%	-4%
10	10=11+12	External operating expenses:	53.875.989	52.852.945	2%
11		Expenses for electricity, natural gas and drinking water	15.011.858	11.479.998	31%
12		Expenses for services performed by third parties	38.864.130	41.372.947	-6%
13	13=8-10	Added Value	257.145.643	283.572.706	-9%
14		Tax and duty expenses	40.307.269	39.100.201	3%
15		Employee benefit expenses	125.742.847	114.310.723	10%
16		Depreciation expenses	39.365.429	33.044.582	19%
17		Adjustments for depreciation of current assets, net	-10.465.028	-2.842.436	268%
18		Other operating income	791.617	2.453.220	-68%
19		Other operating expenses	2.235.023	6.266.726	-64%
20	20=13-14-15-16+/-17+18-19	Other operating expenses (EBIT)	60.751.720	96.146.130	-37%
21		Financial result	-8.928.778	-3.955.249	126%
22		Total income	498.212.639	511.050.765	-3%
23		Total expenses	446.389.697	418.859.882	7%
24		Gross result	51.822.942	92.190.881	-44%
25		Income tax	9.185.720	4.254.353	116%
26		Net result	42.637.222	87.936.528	-52%
27	27=24/2	Gross profit margin (EBT margin)	11,06%	18,22%	-39%
28		Claw back tax expenses	29.676.468	29.333.420	1%
29	29=(24+28)/2	Gross profit profitability + claw-back tax	17,40%	24,01%	-28%
30	30=26/2	Net profit profitability	9,10%	17,38%	-48%

No.	Calculation method	Indicators	30 .09.2025	30.09 2024	30.09 2025/ 30.09.2024
1		Current assets	588.245.150	462.399.037	27%
2		Cash and cash equivalents	14.453.940	28.907.231	-50%
3		Short-term bank debts	116.518.865	33.321.913	250%
4		Total bank debts	256.907.264	121.714.913	111%
5		Net book assets (equity)	922.941.466	879.234.402	5%
		Earnings before interest, taxes, depreciation, and amortization (EBITDA) cumulative 12 months	123.372.542	140.517.437	-12%
6	6=(1-2)/3	Current liquidity (>1.2) (Current assets - cash - current income tax receivable)/Short-term bank liabilities	4,92	13,01	-62%
7	7=4/31	Total bank debts /EBITDA (<3.5)	2,08	0,87	140%
8	8=4/5	Total bank debt /Equity (<1)	0,28	0,14	101%
9		Indebtedness (Total debts/Total assets)	34,09%	29,16%	17%
10		Overall solvency (Total assets/Total liabilities)	2,93	3,32	-12%

No.	Calculation method	Indicators	30 .09.2025	30.09 2024	30.09 2025/ 30.09.2024
11		Working capital (FR) (permanent capital -fixed assets)	323.091.815	239.636.960	35%
12		Working capital requirement (NFR) (Inventories+Receivables-Trade payables)	425.156.740	291.949.907	46%
13		Net treasury (FR-NFR)	-102.064.925	-52.312.947	95%

The gross margin indicator reflects the performance of the company's sales and production activity. The activity carried out in the reference period led to a gross margin of 64.3%. The *value added* indicator reflects what the company adds to the economic circuit through its own activity, the level achieved being 257.15 million lei. in the analyzed period.

The EBIT indicator (operating result) showed a value of 60.75 million lei, with an operating profit margin of 13%. The 12-month cumulative EBITDA, which reflects earnings before interest, taxes, depreciation, and amortization, showed a value of 123.4 million lei.

Current liquidity indicates the maintenance of short-term financial balance and is determined as the ratio between current assets and short-term bank liabilities. The level achieved as of September 30, 2025, was 4.92 (over the level agreed by the banking institutions, i.e. 1,2). Our company has the capacity to meet its current banking obligations through its liquid assets.

The total bank debt to EBITDA ratio stood at 2.08, being within the parameters agreed upon by financial institutions (maximum allowed level of 3.5). The total bank debt to equity ratio stood at 0.28, also within the parameters agreed upon by financial institutions (maximum accepted level of 1).

The indicator "degree of indebtedness" reflects the company's ability to cover total debts from total assets, recording a level of 34.09% , higher compared to the percent recorded on 30.09.2024 of 29.16%. General solvency reflects a company's ability to meet all its obligations, recording a level of 2.93, lower compared to the percent recorded in the same period of 2024, i.e. 3.32.

Value of the working capital below the value of the working capital requirement determined a value of the net treasury indicator of -102.06 million lei, which reflects a temporary gap in the financing of working capital that the company manages through short-term bank loans.

The Working Capital indicator highlights the sustainable resources remained at the company's disposal after financing the fixed assets. On 30.09.2025, the working capital amounted to 323.09 million lei, higher by 35% compared to the value recorded in the same period of the previous year of 239.63 million lei. In January 2025, our company drew the second tranche of the loan contracted with the European Investment Bank in 2023.

The Working Capital requirement indicator highlights the company's short-term financial needs compared to the resources attracted in the short-term. On 30.09.2025, the increase in receivables and inventories, along with the decrease in trade payables led to an indicator value of 425.16 million lei.

Profitability of gross profit + clawback tax was 17.4% on 30.09.2025.

The Income and Expenditure Statement as of September 30, 2025, compared to the values as of September 30, 2024, is presented as follows:

Financial Indicators	30 .09.2025	30.09 2024	30.09 2025/ 30.09.2024
<u>A. Total income, of which:</u>	498.212.639	511.050.764	-3%
1. Operating income	484.383.026	506.610.648	-4%
1.1 Revenue from contracts with customers (turnover), of which:	468.355.688	506.052.026	-7%

income from the sale of products made on their own sites	367.675.106	403.210.601	-9%
income from the sale of products made on partner sites	99.088.807	101.777.669	-3%
income from the provision of services	1.591.775	1.063.756	50%
1.2 Other operating income	458.335	2.143.232	-79%
1.3 Revenue from subsidies	333.282	309.988	8%
1.4 Changes in finished goods inventories and work in progress	7.429.099	-10.083.362	-174%
1.5 Revenue from fixed assets projects	7.806.622	8.188.764	-5%
2. Financial income	13.829.614	4.440.116,2	211%
Income from exchange rate differences	13.828.135	4.438.370	212%
Bank interest income	1.479	1.747	-15%
B. Total expenses, of which:	446.389.697	418.859.883	7%
1. Operational expenses:	423.631.306	410.464.518,18	3%
Expenses on raw materials and supplies	113.251.279	106.404.034,26	6%
Expenses with products made on partner sites	59.317.539	61.327.743,13	-3%
Electricity expenses	6.475.533	5.766.805,33	12%
Natural gas expenses	6.854.817	4.192.823,50	63%
Expenses for drinking water and sewage	1.681.509	1.520.369,61	11%
Employee benefit expenses	125.742.847	114.310.723	10%
Other operating expenses (*)	70.942.354	83.897.437,25	-15%
Depreciation and impairment of fixed assets, net	39.365.429	33.044.582	19%
2. Financial expenses	22.758.391	8.395.365	171%
Expenses from exchange rate differences	19.386.666	4.994.461	288%
Bank interest expenses	3.371.725	3.400.903	-1%
Operational result	60.751.720	96.146.130	-37%
Financial result	-8.928.778	-3.955.249	126%
Gross profit	51.822.942	92.190.881	-44%
Income tax expenses	9.185.720	4.254.353	116%
Net profit	42.637.222	87.936.528	-52%

On 30.09.2025, Antibiotice S.A. recorded a **total income** in value of 498.21 million lei. This income included:

- operating income amounted to 484.38 million lei;
- financial income amounted to 13.83 million lei, including income from exchange rate differences and interest income.

Total expenses incurred to generate revenues were in value of 446.39 million lei, of which:

- operating expenses were in value of 423.63 million lei;
- financial expenses were in value of 22.76 million lei.

Gross profit amounted to 51.82 million lei.

Operating profit recorded a value of 60.75 million lei.

Financial result - the financial challenges and exchange rate market volatility negatively impacted the financial result, which amounted to -8.93 million lei, below the negative financial result of -3.96 million lei recorded in the first 9 months of the year.

Indicators (lei)	30.09.2025	30.09.2024
Financial result	-8,928,778	-3,955,249
Financial income	13,829,614	4,440,116
- Favorable exchange rate differences - cash balance	1,169,189	325,104
- Favorable exchange rate differences - receivables and debts	12,381,857	3,985,921
- Favorable exchange rate differences - credits investments	277,090	127,345
- interest income	1,479	1,747

Indicators (lei)	30.09.2025	30.09.2024
Financial result	-8,928,778	-3,955,249
Financial expenses	22,758,392	8,395,365
- Unfavorable exchange rate differences - available in account	1,434,821	414,454
- Unfavorable exchange rate differences - receivables and debts	14,373,171	4,459,289
- Unfavorable exchange rate differences - investment loans	3,578,674	120,719
- interest expenses	3,371,725	3,400,903

In the structure of operating expenses, **expenses for raw materials and consumable supplies** were 6% higher compared to the value recorded at 30.09.2024 and were in line with the production structure and specific consumption related to the output achieved.

In the structure of operating expenses, expenses for products made on other sites amounted to 59.32 million lei (lower by 3% compared to the value of these expenses incurred on 30.09.2024) in correlation with the income of 99.1 million lei from their sale.

On 30.09.2025, the **expenses for electricity, natural gas, drinking water** amounted to 15 million lei, over the level recorded on 30.09.2024, i.e. 11,5 million lei, an increase influenced by the production structure being driven by the higher quantitative consumption of utilities (an impact of 0.86 million lei) and by increase in the price of utilities (an impact of 3.28 million lei).

The **employee salary expenses** amounted to 125.74 million lei, higher than the value recorded on 30.09.2024 (114.31 million lei), an increase determined by the updating of employee remuneration and motivation systems applied starting with November 2024, and June 2025 respectively.

Other operating expenses - in value of 70.94 million lei, lower by 15% compared to the level recorded in the same period of the previous year, the main expenses being detailed below:

Indicators	30.09 2025	30.9. 2024	30.09 2025/ 30.09.2024
Total other operating expenses, of which:	70.942.354	83.897.437	-15%
Expenses with other taxes and duties	40.307.269	39.100.201	3%
Expenses for services performed by third parties and promotion	26.877.445	27.991.231	-4%
Transportation expenses	3.039.290	3.362.981	-10%
Insurance premium expenses	2.509.578	2.935.725	-15%
Repair expenses	2.038.664	1.695.959	20%
Travel expenses	1.038.078	1.391.135	-25%
Environmental protection expenses	1.010.196	768.385	31%
Representation expenses in territories	571.645	496.061	15%
Provisions for risks and expenses	-10.514.679	-2.842.436	

On 30.09.2025, the main expenses included in the category of other operating expenses:

- ✓ **expenses with taxes and duties** were in value of 40.31 million lei. Out of this value, 29.7 million lei (73.6%) was the claw back tax, up 1.2% compared to the level recorded on 30.09.2024, i.e. 29.33 million lei. According to GEO no. 77/2011 on the establishment of contributions for financing certain expenses in the field of health, for prescription drugs, included in national health programs, with or without personal contribution, used in outpatient treatment based on medical prescription through open-circuit pharmacies as well as for those used in hospital treatment, borne from the National Single Health Insurance Fund and from the budget of the Ministry of Health,

the clawback tax is paid quarterly to the State Budget. Expenses with taxes and fees also include expenses with taxes and local fees for buildings and means of transportation.

- ✓ **expenses for services performed by third parties and promotion** - include services for sales support, advertising and publicity expenses (which include media expenses, expenses related to product shelf positioning projects, scientific promotion and participation in congresses, promotional materials), drug serialization, market studies in the pharmaceutical field, equipment qualifications and maintenance, customs services, physical-chemical analyses, Their value was 26.88 million on 30.09.2025 lei, by 4% lower compared to the value recorded on 30.09.2024 , i.e. 28 million lei. Approval of expenses for services performed by third parties was carried out only upon presentation of their necessity and clearly defined effects, and advertising and publicity expenses were in line with the promotion policy strategy.
- ✓ **transport expenses amounted to 3.04 million lei**, incurred for transportation of finished products delivered free to destination (FDD), sold on the domestic and international markets were by 10% lower than those incurred in the same period of the previous year.
- ✓ **insurance premium expenses** were in value of 2.51 million lei, lower by 15% compared to the value recorded on 30.09.2024. These expenses include insurance premiums paid to cover commercial risk, optional health insurance granted to employees based on performance criteria, accident insurance for employees, mandatory civil liability insurance and casco for vehicles in the fleet, insurance of goods during transport, insurance for consumption of Antibiotice medicines traded on the US market, insurance payment for the 2.5MW photovoltaic park.
- ✓ **maintenance and repair expenses recorded a value of 2.04 million lei**, necessary for maintaining production equipment in optimal condition, consolidating various buildings, maintaining and repairing the car fleet.
- ✓ **travel expenses** recorded a value of 1.04 million lei, below the level recorded in the same period of 2024, i.e. 1.4 million lei. Diversity of activities carried out in the company, with specific legal regulations, involves traveling to authorities, to business partners, both in the country and abroad, to consolidate and develop new partnerships, participation in conferences and international events in the pharmaceutical field, as well as in professional training courses.
- ✓ **environmental protection expenses** consist of amounts paid to the electricity supplier for green certificates, which represent the main share, as well as environmental fees paid to authorized providers for waste recycling. These expenses amounted to 1 million lei, by 31% higher compared to those incurred on 30.09.2024.
- ✓ **representation expenses in territories** on 30.09.2025 were in value of 0.57 million lei, higher by 15% compared to the level achieved in the previous year. Selling products in the Antibiotice S.A. territories involves concluding contracts with partners in the respective areas to manage product registration with authorities and to mediate sales in the market.
- ✓ **provisions for risks and expenses** represent the reversal of adjustments for current assets, recognized upon the sale of products for which adjustments were previously made in accordance with legal requirements. Their value was 10.51 million lei.

Statement of financial position

Indicators	30.09.2025	31.12. 2024	30.09.2025/ 31.12. 2024
	(unaudited)	(unaudited)	
Assets			
Fixed assets			
Tangible fixed assets	745,816,728	749,395,619	-0.48%

Indicators	30.09.2025	31.12. 2024	30.09.2025/ 31.12. 2024
Intangible assets	66,282,456	55,168,937	20.14%
Total fixed assets	812,099,184	804,564,556	0.94%
Currents assets			
Stocks	198,448,283	169,858,775	16.83%
Trade and similar receivables	369,287,301	298,073,567	23.89%
Expenses recorded in advance	6,055,626	4,078,280	48.48%
Cash and cash equivalents	14,453,940	2,681,342	439.06%
Total current assets	588,245,150	474,691,964	23.92%
Total assets	1,400,344,334	1,279,256,520	9.47%
Equity and liabilities			
Equity			
Subscribed capital	67,133,804	67,133,804	0.00%
Revaluation reserves	204,984,246	213,945,112	-4.19%
Legal and other reserves	422,087,411	412,159,000	2.41%
Retained earnings	228,736,005	201,070,907	13.76%
Total equity	922,941,466	894,308,823	3.20%
Long-term debts			
Bank loans and debts	140,388,399	85,715,093	63.78%
Investment subsidies - non-current portion	10,343,715	5,145,731	101.02%
Deferred tax liabilities	61,517,419	59,031,869	4.21%
Total long-term debt	212,249,533	149,892,693	41.60%
Current liabilities			
Trade and similar debts	136,571,278	169,233,444	-19.30%
Bank loans	116,518,865	54,994,289	111.87%
Other debts	11,756,903	10,310,387	14.03%
Investment subsidies - current portion	306,289	516,884	-40.74%
Total current liabilities	265,153,335	235,055,004	12.80%
Total liabilities	477,402,868	384,947,697	24.02%
Total equity and debts	1,400,344,334	1,279,256,520	9.47%

Analysis of fixed assets

Investing in business development and consolidation is one of the priority objectives of the company's business plan.

Since the beginning of 2025, the **inflows of tangible and intangible fixed assets**, combined with the value of depreciation expenses, resulted in a level of net fixed assets of 812.1 million lei on 30.09.2025, a level close to the value recorded at the beginning of 2025 (+1%).

- On 30.09.2025, the net book value of **tangible assets** in the patrimony of Antibiotice S.A. was 745.82 million lei.

Intangible assets, represented by know-how, research and development projects that reached the development phase, software licenses were in value of 66.28 million lei, by 20% higher compared to the value recorded at the beginning of 2025.

Current assets analysis

Current assets increased by 113.55 million lei (+24%) on 30.09.2025 compared to the value recorded at the beginning of the year. The increase is driven by the higher value of trade receivables, correlated with the sales volume and the average collection period of receivables from the domestic market (179 days) and the international market (50 days).

On 30.09.2025, the level of stocks was 198.45 million lei, by 17% higher compared to the value recorded at the beginning of the year. The main categories of stocks:

- Raw materials and consumables (70.64 million lei), a level close to the amount recorded at the beginning of the year. These have an optimal level adapted to the production plan and supply rhythms on the domestic and international market.
- Finished products manufactured on our own sites and on the partner sites in value of 123.19 million lei, in line with the sales plans on the domestic and international markets and with the delivery terms.

In total current assets, the share of receivables was 62.8%, remaining at the same level as at the beginning of the year.

In order to mitigate the commercial risks, our company concluded insurance policies for receivables from both the domestic and international markets.

Cash and cash equivalents amounted to 14.45 million lei on 30.09.2025, coming from financing from the European Investment Bank, used for investment payments.

Analysis of current and long-term debts

Current liabilities as of 30.09.2025 amounted to 265 million lei, 13% higher compared to the value at the beginning of 2025. They include:

- short-term loans amounted to 116.52 million lei, a higher value compared to the beginning of 2025, because our company contracted in May 2025 a short-term credit from Transilvania Bank, for financing the operational suppliers;
- trade and similar payables include:
 - liabilities to suppliers of raw materials, materials, and services, within the due term, amounting to 79.8 million lei, by 7.3% lower compared to those recorded at the beginning of the year;
 - liabilities to fixed asset suppliers, within the due term, amounting to 24.26 million lei;
 - salary-related contributions and taxes outstanding at the end of September 2025, due on 25.10.2025;
 - dividends payable, distributed from the 2024 profit, outstanding at the end of September 2025, amounting to 11.39 million lei;
 - current tax liabilities are represented by the amounts owed to the State Budget, due on 25.10.2025 - income tax (0.28 million lei), contribution to the Solidarity Fund, regulated by Law no. 448/2006 on the protection and promotion of the rights of persons with disabilities (0.28 million lei), the added-value tax in value of 1.7 million lei) and 25.11.2025 - clawback tax - the outstanding balance amounted to 9.5 million lei.

Our company does not record outstanding obligations to the state budget.

Cash flow, prepared using the indirect method, was determined starting from gross profit, corrected with the influences of non-monetary operations (depreciation expenses of fixed assets, adjustment of current assets) and with the variation of working capital elements, with payments for investments and their financing sources.

Subsidies for short-term investments in the amount of 0.31 million lei were represented by the amounts recorded as income as the investments were amortized, respectively:

- subsidies for investments in environmental protection for the Wastewater Treatment Plant;

- European funds for the project POIM COD SMIS 2014-109717 "Intelligent energy consumption monitoring system";
- the 2.5MW photovoltaic power plant for which funding was received from the Ministry of Energy through the National Recovery and Resilience Plan.

On the long run, our company aims at consolidating its net accounting assets; on 30.09.2025, its value amounted to 922.94 million lei, by 3.2% higher compared to the value recorded on 31.12.2024.

Our financial results recorded on 30.09.2025 reflect a challenging economic context compared to the same period of the previous year. Although the indicators show a slight decline, the company maintains its financial stability and continues to invest in strategic projects aimed at ensuring sustainable and profitable growth.

On 30.09.2025, the achieved level of the economic and financial indicators provided for in Regulation no. 5/2018 on issuers of financial instruments and market operations is presented as follows:

Indicators	Calculation method	UM	30.09.2025	30.09.2024
Current liquidity	Current assets/current debt	Number of times	2.22	2.25
Degree of indebtedness	Borrowed capital / Equity *100	%	27.84%	13.84%
Customer receivables turnover rate	Average customer balance /Turnover*Time	days	172	144
Fixed assets turnover ratio	Turnover/Fixed assets	Turnover ratio	0,58	0.65

Investments

The value of fixed assets is closely correlated with the implementation of the investment program, with the investments made in the first nine months of 2025 amounting to 47.26 million lei.

According to the 2025 Annual Program, the investment structure is as follows:

I. Investments in strategic development - in the first 9 months - 28.01 million lei

1. Product portfolio development

During this period, investments in research and development projects continued, aiming to obtain new products that are high-quality, safe, effective, and competitive in the market. The program for developing new products in 2025 has the following objectives: (a) to update the product portfolio and (b) to provide pharmaceuticals competitive on the external market.

2. InvestEU - Investments in new production sites

The project " Production, packaging and storage for sterile products, solutions and topicals" is part of the 2030 Business Plan of Antibiotice SA. This investment covers the 3 stages for the injectable products and sterile topicals on the Antibiotice industrial site: production, packaging and storage. The storage component was completed. The Finished Products Warehouse was authorized by NAMMDR during the first quarter of 2025. For the production component, procedures were carried out to conclude design and execution contracts for the two manufacturing flows and are in various stages of implementation.

The project "INOVA a+ Research-Development Center and production of critical medicines", with partial financing (52%) through the Health Program is in the evaluation stage of the financing contract with the Ministry of Investments and European Projects. Also, the technical and detailed execution projects are in advanced stages of development, and after the signing of the financing contract and the completion of the design, the procedures for the acquisition of construction works and equipment acquisitions will be started.

This project is part of the projects that will be financed through the "Strategic Technologies for Europe" (STEP) platform, the platform established by European Union Regulation 795/2024.

3. Digitalization strategy

Within its digitalization and IT plan, Antibiotice has prioritized investments to increase efficiency by reorganizing all processes based on automation and implementing an integrated IT system, modernizing IT networks, and improving cybersecurity, providing a comprehensive working tool.

During the first 9 months, stages of the implementation plan for the integrated information system for managing company resources (ERP) continued, stages that were completed with the entry into production of the information system in June 2025.

II. Investment for consolidating our business - achieved in the first 9 months - 19.25 million lei

1. Adapting the industrial site, utilities supply and distribution, storage of raw materials and finished products, transportation and connection to the national road system to the development trends

In order to modernize the facilities for the production and distribution of utilities, projects that are carried out over several years are in various phases of development, depending on the complexity and costs of the investments, for modernizing: drinking water networks, transformer stations and electricity distribution facilities, steam production and distribution facilities, compressed air facilities, etc. These projects aim to comply with environmental protection legislation and ensure the continuity of technological processes carried out on the site.

2. Investments in the Integrated Management System (Quality, Environment, Sustainability, Occupational Health and Safety)

The investments consisted mainly in the acquisition of equipment for the quality control laboratories. In the first 9 months, investments were made to modernize the quality control laboratories to ensure standards and operational efficiency.

3. Investments in modernizing the existing sites and equipment

In the first 9 months of 2025, procedures were carried out for purchasing equipment, installations, and laboratory equipment to modernize the drug manufacturing flows of the four divisions. It is estimated that by the end of 2025, all manufacturing flow modernization projects will be completed as planned.

Improvement of Corporate Governance systems

Management Board as of 30.09.2025

No	Full name	Position	Independent	Mandate
1	Ioan NANI	Executive administrator/ General Director	No	15.04.2025-15.04.2029

No	Full name	Position	Independent	Mandate
2	Ionut-Sebastian IAVOR	President of the Management Board/ non-executive administrator	No	15.04.2025-15.04.2029
3	Corina-Luminita VULPES	non-executive administrator	Yes	15.04.2025-15.04.2029
4	Laura-Cristina STANISLAV-BOGDAN	non-executive administrator	No	15.04.2025-15.04.2029
5	Andrei-Tiberiu NOVAC	non-executive administrator	Yes	15.04.2025-15.04.2029
6	Catalin LUNGU	non-executive administrator	Yes	15.04.2025-15.04.2029
7	Post vacant			

Significant events to report for the reference period 01.01.2025-30.09.2025:

- a. On 18.03.2025, the selection of the company's administrators was completed, carried out according to art. 29 of GEO no. 109/2011 by the selection and nomination committee established by administrative act of the Ministry of Health, consisting of 2 members appointed by order of the Minister of Health, 2 members appointed by AMEPIP (Agency for Monitoring and Evaluation of Public Enterprises Performance), by order of the President and an independent expert, selected by AMEPIP. The final report issued by the commission is available on the company's website at <https://www.antibiotice.ro/wp-content/uploads/2024/04/S30C-0i25040916080.pdf>. On 15.04.2025, OGMS appointed, in accordance with art. 29(1) of GEO no. 109/2011, the administrators of the company, from among the administrators proposed by the selection and nomination committee. Information regarding the adopted decisions is available on the company's website at <https://www.antibiotice.ro/investitors-php/financial-information/adunari-generale-ale-actionarilor/>
- b. On 11.06.2025, the selection procedure for the general director was completed, carried out according to art. 35 of GEO no. 109/2011 by an independent expert (legal entity) specialized in human resources recruitment. Information regarding the selection is available on the company's website at <https://www.antibiotice.ro/investitori-php/corporate-governance/procedura-selectie-director-general-2025/>
- c. The Management Board met in 16 sessions between January - September 2025, adopting decisions regarding the company's development strategy, investment programs, company financing, drawing up the 2025-2029 management plan, convocation of the General Meeting of Shareholders.
- d. The Management Board has the *Nomination and Remuneration Committee*, *Risk Management Committee* and the *Audit Committee*, each of them consisting of non-executive directors. The President of each committee is independent.

In the reporting period:

- the administrators developed and approved the Code of Ethics, the Corporate Governance Code, the Organization and Functioning Regulations of the Management Board;
- the *Nomination and Remuneration Committee* participated, together with the independent legal entity expert, in the selection of the company's general director, fulfilling the duties established by art. 35 of GEO no. 109/2011 on the corporate governance of public enterprises. Also, the *Nomination and Remuneration Committee* carried out the procedures established by art. 37 of the same normative act, substantiating and communicating to AMEPIP proposals regarding the remuneration of administrators;
- the *Risk Management Committee* analyzed the Risk Register and made proposals for its update;

- the Audit Committee had meetings with the statutory auditor and analyzed the 2024 financial statements prior to their submission for approval by the General Meeting of Shareholders.

Communication with shareholders and investors

In the first 9 months of 2025, our company organized 7 (seven) General Meetings of Shareholders in which decisions were made regarding the 2025 Revenue and Expenditure Budget, the extension of a credit facility worth 35 million lei opened at the Transilvania Bank, approval of the financial statements and the Management Report for 2024 and the first semester of 2025, Remuneration Policy, 2024 Remuneration Report, profit distribution for 2024, appointment of the company's administrators and approval of their remuneration, approval of the investment project "INOVA a+ Research-Development Center and production of critical medicines" with a total value of 376,877,912.87 lei.

Detailed information regarding the General Meetings of Shareholders of Antibiotice S.A. is available on the company's website at <https://www.antibiotice.ro/investitori-php/financial-information/adunari-generale-ale-actionarilor/>.

Also, 3 teleconferences were held to present the 2024 preliminary financial statements, the financial statements for the first quarter and the first semester of 2025. These events were attended by interested investors and analysts, who asked questions, expressed their opinions and made suggestions, in an open dialogue with the company's representatives. The audio recordings and transcripts of the teleconferences are available on the company's website at <https://www.antibiotice.ro/investitori-php/financial-information/intalnire-cu-investitorii-si-analistii/>.

Risk management

Antibiotice S.A. ensures the organization, functioning and administration of the risk management system at the level of the entire organization as an integral part of the organizational culture in order to achieve the objectives established by "The Future Together" Business Plan. Management adopts a proactive, future-oriented approach to control and limit risks, but also to capitalize on opportunities.

Within the internal organizational structures of Antibiotice SA, specific risks are identified, periodically analyzed and systematically evaluated, developing and updating specific documents, such as: Risk Register, Risk Tracking Sheets, Alert Forms, Control Measures Implementation Plan, Control Measures Implementation Status Report and Risk Profile. Significant risks that exceed the tolerance limit are also analyzed and prioritized, appropriate management measures, implementation deadlines and responsible persons are established. The implementation respects the principle of economic efficiency, ensuring the optimal balance between the resources necessary for risk management and the potential cost of its materialization.

In the third quarter of 2025, implementation of the control measures in the Action Plan was monitored and verified, for the significant risks identified within the organizational structures.

The risk management activities were complemented by preventive measures such as:

- a) monthly monitoring of commercial risk of non-payment - analysis of economic and financial indicators for pharmaceutical distributors;
- b) due diligence analyses of business partners;
- c) analysis of risks and economic-financial indicators for investment projects.

The main categories of risks identified and monitored are:

- business risks (economic, legislative, project, partner-generated);
- financial risks (currency, liquidity, interest rate, commercial);

- taxation risk caused by unpredictability and changes in the fiscal framework, both domestically generated by local government policies, and internationally - related to global fiscal regulations;
- integrity risks and anti-competitive practices;
- operational risks (personnel, information technology, information security, cybersecurity, occupational health and safety, image risk);
- risks and opportunities regarding sustainability aspects.

Through its operations, our company is exposed to the following financial risks:

- commercial (non-payment) risk;
- interest rate risk;
- currency risk;
- liquidity risk.

The management of commercial (non-payment) risk is carried out through the following measures: assessing the creditworthiness of commercial partners, requesting guarantees, monthly monitoring of receivables, insuring them by concluding insurance policies. For external clients, the control of non-payment risk is carried out through insurance and financial instruments, advance payment, the use of letters of credit, collection operations and compensations.

The company's approach to interest rate risk is to optimize the amounts used from operational loans, so as to cover the temporary gap between receipts and payments, use loans in the currency in which payments are made, and simulate macroeconomic scenarios to see the financial impact.

In order to reduce exposure to currency risk, the company has taken a series of measures such as: synchronizing import activity with export activity, by correlating payment and collection terms and correlating the weight of currencies; anticipating collections, correlating payments with collections, monitoring the evolution of the currencies in which payments are made, using operational credits for amounts in the currency in which payments are made, without making currency exchange.

The unpredictability and changes in the fiscal framework generated by local government policies, as well as global tax regulations, have a significant impact on financial stability, management strategies and tax planning. These involve a series of proactive and adaptive measures, such as: constant monitoring and anticipation of national and international tax changes, analysis of the financial impact of new regulations on the activity, identification and implementation of measures to optimize the tax burden and cost management, use of financial models and risk scenarios for decision-making in various economic contexts.

Antibiotice S.A. permanently supervises the operational risks (personnel, technology and information security, cyber, integrity) in order to take measures to maintain them at an acceptable level that does not threaten financial stability, the interests of creditors, shareholders, employees and partners.

Governance policies and practices

In the third quarter of 2025, a change in the shareholding structure was recorded by exceeding the threshold of 5% of total voting rights by **PRIVATELY ADMINISTERED PENSION FUND METROPOLITAN LIFE**.

No conflicts of interest or acts of corruption were reported within the Management Board, directors or employees.

Our company continued to apply the "apply or explain" principle, registering no deviations from the BVB Code.

A clear policy on transactions with affiliated parties is maintained, with all relevant transactions being publicly disclosed in accordance with ASF and BVB regulations.

Internal policies for the procedure of activities are maintained and updated to comply with the principles of fair management of the company's assets, transparency, opportunity, economy, efficiency and decision-making effectiveness.

Personal data protection rules are maintained and updated to ensure compliance with legislation and maintaining customer trust, which contributes to strengthening the reputation.

Perspectives

The Management Board will continue to strengthen corporate governance practices, aiming to:

- increase transparency and decision-making efficiency;
- strengthen the role of advisory committees;
- implement a system of performance indicators (KPI) as a governance mechanism to stimulate decision-making performance.

Events after the reporting period

On 06.11.2025, the General Meeting of Shareholders appointed, by the cumulative vote method, Mrs. Madalina-Anca BONIFATE as administrator of the company with a term of office until 15.04.2029, thus completing the composition of the Management Board in accordance with the Articles of Association.

On 06.11.2025, the General Meeting of Shareholders approved also the performance indicators of the administrators for the period 2025-2029:

Key performance indicators for the executive administrator

Year	Financial indicators					
	Investment policy		Funding	Operations	Return	
	Capital expenditure rate	C&D	Debt/EBITDA ratio	Receivables turnover rate	Operating profit margin	Net turnover growth rate
	%	million lei	nr.	nr.	%	%
2025	2.86%	20	2.18	2.1	17.00%	5.21%
2026	2.86%	20	2.17	2.1	17.00%	5.04%
2027	2.86%	20	2.16	2.1	17.00%	5.34%
2028	2.86%	20	2.15	2.1	17.00%	6.39%
2029	2.86%	20	2.15	2.1	17.00%	5.98%
Indicator weight	10%	10%	5%	10%	5%	10%

Year	Non-financial indicators						
	Operational			Governance		Environment	
	Customer-related indicators	Employee-related indicators	Innovation-related indicators	Indicators related to corporate governance		Sustainability indicators	Environmental indicators
	Customer satisfaction score	Average number of training hours per employee	Share of sales of new services and products	Board meeting attendance rate	Establishing risk management policies	Reducerea intensitatii consumului de apa (mc/CA neta)	Energy consumption

	%	No. hours	%	%	YES/NO	%	MWh
2025	80%	46	0.40%	100%	YES	-1%	0.0240
2026	80%	47	0.50%	100%	YES	-1%	0.0237
2027	80%	48	0.75%	100%	YES	-1%	0.0234
2028	80%	48	1.00%	100%	YES	-1%	0.0231
2029	80%	48	1.00%	100%	YES	-1%	0.0228
Indicator weight	10%	5%	10%	5%	10%	5%	5%

Key performance indicators for non-executive administrators

Year	Investment policy	Funding	Operations	Return		Dividends policy
	CapEx	Current liquidity rate	Inventory turnover rate	Net profit margin	Growth rate of net turnover achieved in the EU (including RO)	Dividend payout rate
	million lei	nr.	nr.	%	%	%
2025	75.00	1.00	4.48	8.00%	7.03%	50.00%
2026	75.00	1.00	4.48	8.00%	7.01%	50.00%
2027	75.00	1.00	4.48	8.00%	7.03%	50.00%
2028	75.00	1.00	4.48	8.00%	7.02%	50.00%
2029	75.00	1.00	4.48	8.00%	7.01%	50.00%
Indicator weight	10%	10%	10%	5%	10%	5%

Year	Non-Financial Indicators						
	Operational			Governance		Environment	
	Customer-related indicators	Employee-related indicators		Indicators related to corporate governance		Sustainability indicators	Environmental indicators
	Customer retention rate	Number of safety trainings	Establishing an employee safety system	Rate of independent members on the Management Board	Number of board meetings	Promoting sustainable procurement - significant % of suppliers (80% of turnover) signatories to the code of conduct for partners	Emissions in scope
	%	nr.	DA	%	nr.	%	tons of CO ₂ e
2025	80%	4	DA	>51%	12	80%	-2.49%
2026	80%	4	DA	>51%	12	80%	-2.49%
2027	80%	4	DA	>51%	12	80%	-2.49%
2028	80%	4	DA	>51%	12	80%	-2.49%
2029	80%	4	DA	>51%	12	80%	-2.49%
Indicator weight	10%	10%	5%	5,0%	5,0%	5%	10%

This Management Report was prepared based on the Interim Financial Statements prepared in accordance with IAS 34 "Interim Financial Reporting".

President of,
Management Board
Ionut-Sebastian IAVOR, Legal Advisor

Executive Administrator/
General Director,
Ioan NANI, Economist

ANTIBIOTICE S.A.

INDIVIDUAL INTERIM FINANCIAL STATEMENTS FOR THE NINE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025

**Prepared in accordance with
International Financial Reporting Standards ("IFRS")
adopted by the European Union**

TABLE OF CONTENTS	PAGE
INDIVIDUAL INTERIM STATEMENT OF THE COMPREHENSIVE INCOME	3
INDIVIDUAL INTERIM STATEMENT OF THE FINANCIAL POSITION	5
INDIVIDUAL INTERIM STATEMENT OF CHANGES IN EQUITY	6
INDIVIDUAL INTERIM CASH FLOWS STATEMENTS	7
EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS	8 – 23

ANTIBIOTICE S.A.

INDIVIDUAL INTERIM STATEMENT OF THE COMPREHENSIVE INCOME
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON")), unless otherwise specified)

	Note	Period ended on September 30, 2025	Period ended on September 30, 2024
		468,355,688	506,052,026
Revenues from contracts with clients, of which:			
<i>Revenues from the sale of finished products</i>	3	367,675,106	403,210,601
<i>Revenues from the sale of products made on other manufacturing sites</i>	3	99,088,807	101,777,669
<i>Income from the provision of services</i>	3	1,591,775	1,063,756
Other operating income	4	458,335	2,143,232
Income from subsidies	4	333,282	309,988
Changes in stocks of finished products and production in progress		7,429,099	(10,083,362)
Income from fixed assets projects		7,806,622	8,188,764
Expenses with raw materials, used consumables and products made on other manufacturing sites	5	(172,568,817)	(167,731,777)
Employee benefit expenses	6	(125,742,847)	(114,310,723)
Transport costs	7	(3,039,290)	(3,362,981)
Utility costs	7	(15,011,859)	(11,479,998)
Amortization and adjustments for the depreciation of fixed assets, net	11,12	(39,365,429)	(33,044,582)
Adjustments for depreciation of current assets, net		10,514,679	2,842,436
Sponsorships, donations		(634,758)	(640,439)
Other expenses	7	(77,782,986)	(82,736,454)
Operational result		60,751,720	96,146,130
Exchange rate differences, net	8	(5,558,531)	(556,092)
Interest expense, net	8	(3,370,247)	(3,399,157)
Other financial expenses	8	-	-
Financial result	8	(8,928,778)	(3,955,249)
Pre-tax profit		51,822,942	92,190,881
Income tax expense	9	(9,185,720)	(4,254,353)
The profit of the financial exercise		42,637,222	87,936,528
Basic/diluted earnings per share		0.0635	0.1310
Profit for the financial year		42,637,222	87,936,528
<i>Other elements of the overall result</i>		-	-
<i>Items that will not be classified in profit or loss</i>		-	-
<i>Revaluation of tangible assets</i>	11	-	-
<i>Deferred tax related to the revaluation of tangible assets</i>	8	-	-
<i>Other elements of the overall result</i>		-	-
Total overall result		42,637,222	87,936,528

Approved by the Management Board on: 13.11.2025

General Director,
Mr. Ioan NANI

Financial Director,
Mrs. Paula Luminita COMAN

ANTIBIOTICE S.A.

INDIVIDUAL INTERIM STATEMENT OF THE COMPREHENSIVE INCOME FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025 (all amounts are expressed in LEI ("RON")), unless otherwise specified)

	3-month period ended on September 30, 2025 (July-September 2025) (unaudited)	3-month period ended on September 30, 2024 (July-September 2024) (revised)
Revenue from contracts with customers, of which:	134,615,680	155,201,952
<i>Revenue from sales of finished goods</i>	111,700,158	118,843,217
<i>Revenue from sales of products made on other manufacturing sites</i>	22,584,939	35,855,249
<i>Revenue from rendering of services</i>	330,583	503,486
Other operating income	62,959	190,388
Revenue from subsidies	125,038	129,221
Changes in inventories of finished goods and work in progress	(22,982,627)	(28,072,272)
Income from fixed assets projects	2,361,443	2,503,835
Expenses for raw materials, consumables and products made at other manufacturing sites	(39,706,653)	(40,251,143)
Employee benefit expenses	(45,846,935)	(38,662,375)
Transportation expenses	(917,592)	(1,102,887)
Utility expenses	(2,493,608)	(2,647,605)
Depreciation and impairment of fixed assets, net	(13,393,452)	(11,456,348)
Adjustments for depreciation of current assets, net	3,500,000	3,526,478
Sponsorships, donations	(216,747)	(352,925)
Other expenses	(29,498,522)	(22,444,224)
Operational result	(14,391,015)	16,562,095
Exchange rate differences, net	(909,326)	(1,382,511)
Interest expenses, net	(1,171,749)	(1,418,538)
Financial result	(2,081,075)	(2,801,049)
	-	-
Pre-tax profit	(16,472,090)	(13,761,046)
Income tax expense	(14,483)	(18,548)
Profit for the financial year	(16,486,573)	13,761,046
Basic and diluted earnings per share	(0,0246)	0,0205
Profit for the financial year	(16,486,573)	13,742,498
Other elements of the overall result	-	-
Items that will not be classified in profit or loss	-	-
Revaluation of tangible assets	-	-
Deferred tax related to the revaluation of tangible assets	-	-
Other elements of the overall result	-	-
Total overall result	(16,486,573)	13,742,498

Approved by the Management Board on: November 13, 2025

General Director,
Mr. Ioan NANI

Financial Director,
Mrs. Paula Luminita COMAN

ANTIBIOTICE S.A.
STATEMENT OF THE FINANCIAL POSITION
FOR THE FINANCIAL YEAR ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in lei ("RON"), unless otherwise stated)

	Note	Period ended on September 30, 2025	Period ended on December 31, 2024
Assets			
Fixed assets			
Tangible fixed assets	10	745,816,728	749,395,619
Intangible fixed assets	11	66,282,456	55,168,937
Total tangible fixed assets		812,099,184	804,564,556
Current assets			
Inventories	12	198,448,283	169,858,775
Trade and similar receivables	13	369,287,301	298,073,567
Expenses registered in advance		6,055,626	4,078,280
Cash and cash equivalents	14	14,453,940	2,681,342
Total current assets		588,245,150	474,691,964
Total assets		1,400,344,334	1,279,256,520
Equity and liabilities			
Equity			
Subscribed capital	15	67,133,804	67,133,804
Revaluation reserves	15	204,984,246	213,945,112
Legal reserves and other reserves		422,087,411	412,159,000
Retained earnings		228,736,005	201,070,907
Total equity		922,941,466	894,308,823
Long-term liabilities			
Loans and bank debts	17	140,388,399	85,715,093
Subsidies for investments - non-current portion	18	10,343,715	5,145,731
Deferred tax liabilities	8	61,517,419	59,031,869
Total long-term liabilities		212,249,533	149,892,693
Current liabilities			
Trade and similar liabilities	16	136,571,278	169,233,444
Bank loans	17	116,518,865	54,994,289
Other debts	16	11,756,903	10,310,387
Subsidies for investments - current portion	18	306,289	516,884
Provisions			
Total current liabilities		265,153,335	235,055,004
Total liabilities		477,402,868	384,947,697
Total equity and liabilities		1,400,344,334	1,279,256,520

Approved by the Management Board on: 13.11.2025

General Director,
Mr. Ioan NANI

Financial Director,
Mrs. Paula Luminita COMAN

ANTIBIOTICE S.A.**INDIVIDUAL INTERIM STATEMENT OF CHANGES IN EQUITY****FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025****(all amounts are expressed in LEI ("RON"), unless otherwise specified)**

DECEMBER 31, 2024	Share capital	Legal reserves and other reserves	Revaluation reserves	Cumulative retained earnings	Total equity
Balance on January 01, 2024	67,133,804	324,877,598	225,417,959	229,534,759	846,964,120
Result of the year	-	-	-	102,202,828	102,202,828
Other comprehensive income	-	-	-	-	-
Total overall result	-	-	-	102,202,828	102,202,828
Reserves representing the surplus realized from revaluation	-	-	(11,472,847)	11,472,847	-
Dividends paid in the first trimester of 2024	-	-	-	(55,669,264)	(55,669,264)
Transfer from the retained earnings over to other reserves	-	87,281,402	-	(87,281,402)	-
Balance on December 31, 2024	67,133,804	412,159,000	213,945,112	201,070,907	894,308,823
SEPTEMBER 30, 2025					
Balance on January 01, 2025	67,133,804	412,159,000	213,945,112	201,070,907	894,308,823
Result of the third semester of 2025	-	-	-	42,637,222	42,637,222
Other elements of the overall result	-	-	-	-	-
Total overall result	-	-	-	42,637,222	42,637,222
Reserves representing the surplus achieved from revaluation	-	-	-	(14,004,579)	(14,004,579)
Dividends paid in the third semester of 2025	-	-	(8,960,866)	8,960,866	-
Transfer from the retained earnings over to other reserves	-	9,928,411	-	(9,928,411)	-
Balance on September 30, 2025	67,133,804	422,087,411	204,984,246	228,736,005	922,941,466

Approved by the Management Board on: 13.11.2025.

**General Director,
Mr. Ioan NANI****Financial Director,
Mrs. Paula Luminita COMAN**

The attached notes are an integral part of the individual interim financial statements

ANTIBIOTICE S.A.

INTERIM INDIVIDUAL STATEMENT OF CASH FLOWS

FOR THE PERIOD ENDED ON SEPTEMBER 30, 2025

(all amounts are expressed in LEI ("RON")), unless otherwise specified)

The indirect method	Note	Period ended on September 30, 2025	Period ended on September 30, 2024
Pre-tax profit		51,822,942	92,190,882
Adjustments for:			
Depreciation related to intangible assets		4,377,484	2,758,055
Depreciation related to tangible assets		35,028,913	30,286,527
Expenses related to inventory provisions		(4,521,103)	(2,840,701)
(Revenues) related to customer provisions and assimilated accounts		(5,993,576)	(1,736)
Expenses related to adjustments for depreciation of fixed assets		8,412,116	(6,635,020)
The net loss from the disposal of tangible assets		10,514,679	2,842,436
Income from subsidies		(333,382)	(309,988)
Interest expense		3,371,725	3,400,903
Interest income		(1,479)	(1,747)
Cash flow generated from operating activity before changes in working capital		102,678,319	121,689,612
(Increases) of stocks		(28,589,508)	(12,682,991)
(Increases)/Decreases in receivables		(71,213,734)	(35,690,414)
(Increases) of expenses in advance		(1,977,346)	(1,630,170)
Increases/(decreases) in liabilities		43,945,366	14,345,942
Increases /(decreases) in debts		(333,382)	(309,988)
Interest paid		(3,371,725)	(3,400,903)
Interest collected		1,479	1,747
Profit tax paid		(6,313,738)	(2,686,521)
Net cash from operating activities		34,825,731	79,636,314
Cash flows from investment activities			
Purchases of tangible assets		(88,506,743)	(48,247,447)
Purchases of intangible assets		(40,778,085)	(3,856,899)
Net cash from investment activities		(129,284,828)	(52,104,346)
Cash flows from financing activities			
(Refund) Credit line usage		56,646,720	3,767,671
(Repayment) of long-term loan		59,551,161	26,917,108
Dividends paid		(9,966,186)	(31,117,447)
Net cash from financing activities		106,231,695	(432,667)
(Decrease)/Net increase in cash and cash equivalents		11,772,598	27,099,301
Cash and cash equivalents at the beginning of the financial year	15	2,681,342	1,807,930
The effect of the exchange rate on the movement of cash and cash equivalents			
Cash and cash equivalents at the end of the financial year	15	14,453,940	28,907,231

Approved by the Management Board on: 13.11.2025

General Director,
Mr. Ioan NANI

Financial Director,
Mrs. Paula Luminita COMAN

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON"), unless otherwise specified)**

1. COMPANY RELATED INFORMATION

1.1. Company overview

Antibiotice S.A. ("ATB" - Bucharest Stock Exchange symbol, "The Company") is a commercial company established in Romania, with registered office at Str. Valea Lupului, nr. 1, Iasi. The company is registered at the Trade Registry Office under no. J1991000285223 and it has the unique registration code 1973096.

The scope of activity of Antibiotice S.A. is the manufacture of basic pharmaceutical products, according to the Classification of Economic Activities in the National Economy, CAEN code 2110.

These are the individual interim financial statements of Antibiotice S.A. drawn up on 30.09.2025, which were authorized on 13.10.2025.

Antibiotice S.A.:

- is the most important manufacturer of generic medicines in Romania, owned entirely by the Romanian state;
- is the only Romanian company that produces active substances through biosynthesis processes;
- has been listed on the Bucharest Stock Exchange in the premium category, since 1997;
- has a product portfolio that includes generic medicines for human use (RX medicines and non-RX products), active substances based on biotechnologies derived from *Streptomyces noursei* for pharmaceutical use (in the form of compacted Nystatin, micronized Nystatin and standard Nystatin), biocidal products for surface and hand disinfection, veterinary medicines and biofertilizers. The product portfolio consists of over 160 products from 11 therapeutic classes. Prescription products are mainly grouped by ATC1 therapeutic classes and are intended for pathologies with high incidence and the treatment of chronic conditions. Non-prescription products are grouped into portfolio concepts, for more efficient communication to the target audience. The concepts include food supplements, medical devices, cosmetics, OTC medicines and OTX medicines (RX products with OTC behavior being dispensed from pharmacies without a prescription). The products in the current portfolio are carefully monitored, with actions being taken to adapt to national requirements and international regulations, through the analysis of therapeutic trends, medical guidelines, new efficacy and safety studies. The expansion of the product portfolio contributes greatly to the development of Antibiotice S.A. on the domestic market, as well as on international markets, both through its own research and development activity and by assimilating new products through business development (in-licensing contracts).
- has a diversified production capacity, organized on 3 production divisions, 8 manufacturing flows on which: penicillin injectable powders are produced; penicillin capsules; non-beta-lactam capsules; cephalosporin capsules; tablets; ointments, creams, gels; suppositories; pessaries; active substances obtained through biosynthesis and 10 partner sites. All the production capacities are the property of the company and they are located at the registered office. The company has the right of ownership over all the fixed assets registered in the company's accounting;
- owns a modern Research and Development Center;
- holds internationally recognized certifications and authorizations: authorization from the US Medicines Regulatory Agency (FDA) for Nystatin and injectable penicillin products, Certificate of Conformity with the European Pharmacopoeia (COS) for Nystatin, Certificate of Good Manufacturing Practice (GMP) for all manufacturing flows, TÜV Rheinland Certification for integrated management (quality, environment, occupational health and safety);
- is WHO prequalified and has WHO certification for the range of essential antituberculosis drugs;
- is a traditional supplier of anti-infective drugs for hospitals in the USA, Vietnam and European markets (Great Britain, Denmark, The Netherlands, Serbia, Lithuania, Hungary);
- is the world market leader for the consumption of active substances based on biotechnologies derived from *Streptomyces noursei* for pharmaceutical use (in the form of compacted Nystatin, micronized Nystatin and standard Nystatin). The superior quality of this product, recognized by the US authorities (FDA) as an international reference standard, is reflected in a continuous increase in the number of new customers in Europe, South America and North America.

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON")), unless otherwise specified)**

2. MAIN ACCOUNTING POLICIES

The individual interim financial statements were drawn up in accordance with the provisions of the Order no. 2844/2016 for the approval of the accounting regulations in accordance with the International Financial Reporting Standards applicable to commercial companies whose securities are admitted to trading on a regulated market, with subsequent regulations and clarifications. These provisions comply with those of the International Financial Reporting Standards adopted by the European Union. The individual interim financial statements were drawn up on the basis of the continuity of the activity.

The accounting policies and evaluation methods adopted for the preparation of individual interim financial statements are consistent with those used for the preparation of the annual financial statements of Antibiotice S.A. on December 31, 2024.

These individual interim financial statements have been prepared in accordance with IAS 1 Presentation of financial statements, as adopted by the European Union. They do not include all the information required for a complete set of financial statements in accordance with IFRS and they should be read together with the Company's annual financial statements, prepared on December 31, 2024. However, certain selected explanatory notes are included to explain the events and the transactions that are significant for understanding the changes in the company's financial position and performance since the last individual annual financial statements on the date and for the period ending on September 30, 2025.

2.1. Basis of the evaluation

The individual interim financial statements are prepared on the historical cost basis except for land and buildings presented at revalued cost using fair value as deemed cost and for items presented at fair value, namely financial assets and liabilities at fair value, through profit or loss, except for those for which the fair value cannot be reliably determined.

These interim separate financial statements have been prepared for general purposes, for the use of persons familiar with the provisions of the International Financial Reporting Standards, applicable to companies whose securities are admitted to trading on a regulated market. Consequently, these financial statements should not be considered as the sole source of information by a potential investor or other user.

2.2. Crucial accounting evaluations and estimates

The company makes certain estimates and assumptions regarding the future. The estimates and the judgments are continually evaluated based on the historical experience and other factors, including forecasting of future events that are believed to be reasonable under the existing circumstances. In the future, the actual experience may differ from the present estimates and assumptions. Examples of evaluation, estimation, assumptions applied within the company are given below:

- The valuation of land investments and the company owned buildings - Based on the evaluations made by external assessors, the fair value of real estate investments and the company owned buildings is determined. These evaluations are based on assumptions that include future rental income, anticipated maintenance costs, future development costs and the discount rate. The evaluators also refer to the information on the market related to the prices of transactions with similar properties.
- The adjustments for the impairment of receivables – For trade receivables, a simplified approach is adopted in which the impairment losses are recognized based on the expected lifetime credit losses at each reporting date. If there are credit insurances or guarantees for outstanding balances, the calculation of expected losses from receivables is based on the probability of non-repayment of the insurer for the insured part of the outstanding balance and the remaining uncovered amount will have the probability of non-repayment of the counterparty. For the trade receivables, the simplified model regulated by IFRS 9 is used.
- Adjustments for inventory impairment - The assessment for inventory impairment is performed on an individual basis and it is based on the management's best estimate of the present value of cash flows expected to be received. Each impaired asset is analyzed individually. The accuracy of the adjustments depends on the estimation of future cash flows. The adjustments regarding stocks are based on the calculation performed at the end of the financial year for the specific value adjustment related to stocks of raw materials, consumables and finished products that no longer comply from a qualitative viewpoint. The calculation of the general adjustment for stock depreciation is made according to the validity period of the items in stock.
- Judicial proceedings - The company reviews the unresolved legal cases following the developments in the judicial proceedings and the existing situation at each reporting date, in order to evaluate the provisions and the presentations of its financial statements. Among the factors considered in making decisions related to provisions are the nature of the litigation or claims and the potential level of damages in the jurisdiction where the litigation is judged, the progress of the case (including the progress after the date of the financial statements but before those statements are issued), the opinions of the legal advisors,

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON"), unless otherwise specified)**

the experience in similar cases and any decision of the company's management related to the way it will respond to the litigation, complaint or evaluation.

- Accounting estimates of expenses - There are objective situations in which, until the closing date of certain fiscal periods or until the closing date of a financial year, the exact values of certain expenses incurred by the company are not known (e.g. marketing-sales campaigns for product promotion and sales stimulation). For this category of expenses, preliminary estimates of expenses will be made, which will be effectively recorded in the following periods.
- Taxation - The Romanian tax system is in a stage of consolidation and harmonization with the European legislation. There are uncertainties regarding the interpretation of complex tax regulations, changes in tax laws and the amount and timing of future taxable income. Given the diversity of business relationships and the long-term nature and complexity of existing contractual agreements, the differences that arise between the actual results and the assumptions made or future changes to these assumptions could require future adjustments to tax income and expenses already recorded. In Romania, the fiscal year remains open for tax verification for 5 years. The company's management believes that the tax obligations included in the financial statements are adequate.

3. OPERATING INCOME

Below there is an analysis of the revenues:

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
Sales of finished products	446,601,174	463,312,262
Sales of products made on other manufacturing sites	119,286,546	120,910,930
Income from other activities	1,591,775	1,063,756
Trade discounts granted	(99,123,807)	(79,234,922)
Total	468,355,688	506,052,026

According to the geographical distribution, the turnover is structured as follows:

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
On the Romanian market	265,794,427	303,793,032
On foreign markets	202,561,261	202,258,994
Total	468,355,688	506,052,026

4. OTHER INCOME

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
Income from the revaluation of tangible assets	-	-
Income from compensations, fines and penalties	172,473	8,779
Income from the sale of tangible and intangible assets	-	163,500
Other operating income	285,861	1,970,953
Total	458,334	2,143,232
Income from subsidies	333,282	309,988
Total	791,617	2,453,220

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON"), unless otherwise specified)**

5. COSTS OF RAW MATERIALS, USED CONSUMABLES AND GOODS

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
Raw material expenses	101,665,476	93,812,752
Consumables expenses	11,486,734	12,579,872
Expenses with goods	59,317,539	61,327,743
Used packaging	99,069	11,410
Total	172.568.817	167.731.777

6. EXPENSES WITH EMPLOYEE BENEFITS AND REMUNERATION OF THE MEMBERS OF THE MANAGEMENT BOARD

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
Wages	112,776,772	102,265,970
Labor insurance deduction	2,833,656	2,648,548
Meal vouchers and other benefits granted to employees	10,132,419	9,396,205
Total expenses with employee benefits	125,742,847	114,310,723

The remuneration granted to the Management Board and the Executive Management is shown in the table below:

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
Wages	546,582	421,262
Civil contracts	1,490,846	1,112,964
Taxes and social deductions	45,844	116,952
Variable allowances	-	1,654,886
Total	2,083,272	3,306,064

7. OTHER EXPENSES

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
Expenses with services performed by third parties	12,814,164	13,981,664
Repair expenses	2,038,664	1,695,959
Expenses with other taxes and fees*	40,307,269	39,100,201
Protocol, advertising and publicity expenses	15,081,995	14,861,335
Insurance premium expenses	2,509,578	2,935,725
Consultancy expenses	348,447	381,418
Other general expenses	3,001,126	7,234,920
Rent expenses	238,979	238,372
Travel expenses	1,038,078	1,391,135
Expenses with postal and telecommunications fees	394,714	539,858
Expenses for compensation, fines and penalties	9,972	375,867
Expenses for revaluation of tangible assets	-	-
Expenses related to assets disposed of	-	-
Total	77,782,986	82,736,454

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON"), unless otherwise specified)**

7. OTHER EXPENSES (continued)

The other general expenses in the amount of 3,001,126 lei recorded on 30.09.2025 include:

- Environmental protection expenses in the amount of 1,010,197 lei;
- Expenses for supporting international sales, in the amount of 571,645 lei;
- Professional training expenses, in the amount of 505,723 lei;
- Expenses with bank commissions in the amount of 459,364 lei;
- Expenses with losses from receivables and various debtors in the amount of 49,650 lei;
- Income from operating subsidies for operating expenses -175,551 lei;
- Other operating expenses in the amount of 580,097 lei.

Other general expenses in the amount of 7,234,920 lei recorded on 30.09.2024 include:

- Environmental protection expenses in the amount of 960,693 lei;
- Expenses for supporting international sales, in the amount of 496,061 lei;
- Professional training expenses in the amount of 900,095 lei;
- Expenses with bank commissions in the amount of 396,035 lei;
- Other operating expenses in the amount of 4,482,035 lei (the annual analysis of research projects led to the recording of the amount of 3,809,084 lei representing research projects that will not be completed).

***Expenses with other taxes and fees**

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
Expenses on the tax on buildings	1,920,104	1,566,072
Special construction expenses	315,214	-
Land tax expenses	511,845	511,230
Expenses on the tax on means of transport	45,844	31,923
Expenses on other taxes and fees	5,205,278	7,604,188
Solidarity fund tax expenses	703,041	-
Expenses on the tax for the registration of licenses	-	-
Expenses related to the environmental fund	28,590	47,148
Expenses on company taxes and advertising	1,900,885	6,220
Clawback fee charges	29,676,468	29,333,420
Total	40,307,269	39,100,201

8. FINANCIAL RESULT

Financial income and expenses:

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
Interest expenses	(3,371,725)	(3,400,904)
Interest income	1,479	1,747
Interest expense, net	(3,370,247)	(3,399,157)
Income from exchange rate differences	13,828,135	4,438,370
Expenses from exchange rate differences	(19,386,666)	(4,994,462)
Exchange rate differences, net	(5,558,531)	(556,092)
Other financial expenses	-	-
The financial result	(8,928,778)	(3,955,249)

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025**
(all amounts are expressed in LEI ("RON"), unless otherwise specified)

The interest expenses relate to loans from banks, which are valued at amortized cost.

9. EXPENSES WITH CURRENT PROFIT TAX AND DEFERRED TAX

Amounts recognized in profit or loss

	Period ended on September 30, 2025	Period ended on September 30, 2024
	RON	RON
Current income tax expenses	2,808,308	5,384,927
Minimum corporate tax expenses	3,891,862	-
The impact of deferred income tax	2,485,550	(1,130,574)
Total	9,185,720	4,254,353

The profit tax

The current profit tax for 9 months in 2025 and 2024 is determined at a statutory rate of 16% based on the adjusted accounting profit with the non-deductible expenses and the non-taxable income. The final value of the profit tax is reduced by tax credits.

	Period ended on September 30, 2025	Period ended on September 30, 2024
Accounting profit:	32,551,748	105,680,918
Tax at the Romanian corporate tax rate of 16%	5,208,280	16,908,947
Profit tax at the level of the minimum turnover tax	3,891,862	-
Effect of non-deductible expenses	4,248,780	6,540,327
The effect of non-taxable income	(3,340,191)	(4,675,609)
Tax related to reinvested profit	(1,778,256)	(10,904,046)
Other tax effects	955,245	(3,615,266)
Income tax expenses	9,185,720	4,254,353

ANTIBIOTICE S.A.

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON"), unless otherwise specified)**

10. FIXED TANGIBLE ASSETS

	Land	Buildings	Machinery and equipment, vehicles	Installation s and furniture items	Tangible fixed assets in progress	Total
COST						
Balance on January 1, 2024 (audited)	204,794,472	312,770,025	286,240,810	10,234,687	42,671,079	856,713,072
Increases:	-	-	-	-	98,774,675	98,774,675
Transfers to/from fixed assets in progress	-	65,581,495	52,081,165	3,158,442	(120,873,476)	-
Disposals and other discounts	-	(744,329)	(7,157,185)	(60,561)	-	(7,962,075)
Balance on December 31, 2024	204,794,472	377,607,191	331,164,790	13,332,568	20,572,278	947,471,299
Balance on January 1, 2025	204,794,472	377,607,191	331,164,790	13,332,568	20,572,278	947,471,299
Increases:	-	-	-	-	49,241,722	48,670,132
Transfers to/from fixed assets in progress	-	7,962,684	19,463,414	143,352	(44,850,037)	(16,708,997)
Disposals and other discounts	-	(516,828)	(7,729,656)	(195,190)	-	(8,441,674)
Balance on September 30, 2025 (unaudited)	204,794,472	385,053,047	342,898,549	13,280,730	24,963,963	970,990,760

ANTIBIOTICE S.A.

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON"), unless otherwise specified)**

10. FIXED TANGIBLE ASSETS (continued)

	Land	Buildings	Machinery and equipment, vehicles	Installations and furniture items	Tangible fixed assets in progress	Total
CUMULATED DEPRECIATION						
Balance on January 1, 2024 (audited)	-	118,996	157,293,502	6,939,034	-	164,351,532
Depreciation recorded during the year	-	22,283,783	18,258,169	526,883	-	41,068,835
Disposals and other discounts	-	(126,941)	(7,157,185)	(60,561)	-	(7,344,687)
Balance on December 31, 2024 (audited)	-	22,275,838	168,394,486	7,405,356	-	198,075,680
Balance on January 1, 2025 (audited)	-	22,275,838	168,394,486	7,405,356	-	198,075,680
Depreciation recorded during the year	-	18,114,549	16,350,363	523,438	-	34,988,350
Disposals and other discounts	-	-	(7,694,809)	(195,190)	-	(7,889,999)
Balance on September 30, 2025	-	40,390,387	177,050,040	7,733,604	-	225,174,031
NET BOOK VALUE						
Net book value on December 31, 2024 (audited)	204,794,472	377,607,190	331,164,791	13,332,568	20,572,278	947,471,300
Net book value on September 30, 2025 (unaudited)	204,794,472	344,662,660	165,848,508	5,547,126	24,963,963	745,816,728

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON")), unless otherwise specified)**

10. FIXED TANGIBLE ASSETS (continued)

The most important investment projects carried out in 2025 are the following:

1. Product portfolio development

During this period, investments in research and development projects continued in order to obtain new, quality, safe, efficient and competitive products on the market. The new product development program for 2025 has the following objectives: (a) modernizing the company's product portfolio and (b) ensuring competitive pharmaceutical products on the external market.

2. Investments in new production sites

The project "Capacity for production, packaging and storage of sterile products, solutions and topicals" is part of the Business Plan of S.C. Antibiotice S.A. for the year 2030. The investment covers the 3 stages for sterile injectable and topical products on the Antibiotice S.A. industrial platform: production, packaging and storage. The warehouse for pharmaceutical products, a part of this project, was completed in 2024. In the first quarter of 2025, the warehouse was audited and authorized by the National Agency for Medicines and Medical Devices.

For the manufacturing flows: for the sterile solutions flow, the design, supply and assembly contract was concluded and currently the contractor Syntegon Germany is designing the flow; for the sterile topical flow, the procedures were carried out for concluding supply contracts for manufacturing equipment and the contracts are currently ongoing.

A very important project has been started: "Inova a+ Research Capacity and Production of Critical Medicines", with partial funding from the Ministry of Investments and European Projects. This project is part of the projects that will be funded by the "Strategic Technologies for Europe" (STEP) platform, the platform established by the European Union Regulation 795/2024. The project consists of building and fully equipping a research capacity for the pharmaceutical field and a penicillin production capacity, with dedicated flows for sterile powders divided into vials and oral solid forms, tablets and suspendable powders. The project is currently in the stage of developing the feasibility study in order to obtain funding.

3. The digitization strategy

Antibiotice S.A., within the digitization and computerization plan, has prioritized investments to increase the company's efficiency, by reorganizing all the processes based on automation and implementing an integrated IT system, modernizing IT networks and improving the IT security to provide a complete work tool.

4. The adapting to the development trends of the industrial platform, utility supply and distribution infrastructures, the storage of raw materials and finished products, the transportation and connection to the national road system.

In order to modernize the facilities for the production and distribution of utilities are in various stages of development; these are projects which are carried out over several years, depending on the complexity and costs of the investments, for the modernization of: drinking water networks, transformer stations and electricity distribution facilities, steam production and distribution facilities, compressed air facilities. These projects aim to comply with the environmental protection legislation and to ensure the continuity of technological processes carried out on the platform.

5. Investments in the Integrated Management System (Quality, Environment, Sustainability and Occupational Health and Safety)

Investments in this chapter consisted mainly of the acquisition of equipment for the equipment of product quality control laboratories. In the first 3 months, investments were made to modernize quality control laboratories to ensure standards and operational efficiency.

6. Investments in modernizing existing sites and equipment

In order to modernize the drug manufacturing flows of the three divisions, in the first 3 months of 2025 the procedures were carried out for the acquisition of equipment, installations, facilities and laboratory equipment. By the end of 2025, all the manufacturing flows modernization projects will be completed according to plan.

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025**
(all amounts are expressed in LEI ("RON"), unless otherwise specified)

11. INTANGIBLE ASSETS

	Concessions, patents and other similar rights (externally generated)	Other intangible assets (internally generated)	Other intangible assets (externally generated)	Development expenses (internally generated)	Development expenses (externally generated)	Total intangible assets
COST						
Balance on January 1, 2024(audited)	13,117,162	20,675,288	4,961,202	31,828,302	1,171,854	71,753,808
Increases	5,821,065	-	-	10,992,826	572,010	17,385,901
Disposals / discounts	(3,037,722)	-	-	(3,809,084)	-	(6,846,806)
Transfers	-	6,584,120	270,725	(6,755,685)	(99,160)	-
Balance on December 31, 2024	15,900,505	27,259,408	5,231,927	32,256,359	1,644,704	82,292,903
Balance on January 1, 2025 (audited)	15,900,505	27,259,408	5,231,927	32,256,359	1,644,704	82,292,903
Increases	16,329,220	-	-	8,003,521	375,186	24,707,927
Disposals / discounts	(9,216,925)	-	-	-	-	(9,216,925)
Transfers	-	4,956,709	216,133	(5,073,682)	(99,160)	-
Balance on September 30, 2025 (unaudited)	23,012,800	32,216,117	5,448,060	35,186,198	1,920,730	97,783,905
Cumulative depreciation						
Balance on January 1, 2024 (audited)	11,811,036	10,105,966	4,310,108	-	-	26,227,110
Depreciation expense	690,172	3,073,544	170,862	-	-	3,934,578
Disposals / discounts	(3,037,722)	-	-	-	-	(3,037,722)
Balance on December 31, 2024	9,463,486	13,179,510	4,480,970	-	-	27,123,966
Balance on January 1, 2025 (audited)	9,463,486	13,179,510	4,480,970	-	-	27,123,966
Depreciation expense	857,776	3,334,179	185,528	-	-	4,377,483
Balance on September 30, 2025 (unaudited)	10,321,262	16,513,689	4,666,498	-	-	31,501,449
Net book value						
On December 31, 2024 (audited)	6,437,019	14,079,898	750,957	32,256,359	1,644,704	55,168,937
On September 30, 2025 (unaudited)	12,691,538	15,702,428	781,562	35,186,198	1,920,730	66,282,456

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON"), unless otherwise specified)**

12. INVENTORIES

	Period ended on September 30, 2025 (unaudited)	Period ended on December 31, 2024 (audited)
	RON	RON
Finished products	75,818,579	72,949,599
Raw materials	66,009,923	72,934,378
Products made on other manufacturing sites	48,818,755	24,902,168
Goods	349,016	84,890
Consumables	16,828	25,265
Inventory items	4,487,282	-
Residual products	2,130	2,469
Packagings	103,039	78,777
Products in progress	4,611,197	5,170,799
Inventories - gross value	200,216,749	176,148,345
Value adjustments for raw materials and supplies	(326,123)	(1,964,160)
Value adjustments for finished products	(1,442,343)	(1,767,036)
Value adjustments for goods	-	(2,558,374)
Total value adjustments	(1,768,466)	(6,289,570)
Total inventories - net value	198,448,283	169,858,775

Stocks are secured and purchased to ensure the continuity of production in the third quarter.

13. TRADE AND SIMILAR RECEIVABLES

	Period ended on September 30, 2025 (unaudited)	Period ended on December 31, 2024 (audited)
	RON	RON
Short-term receivables		
Trade receivables	341,681,227	311,936,942
Customers – invoices to be prepared	(28,402,280)	(19,937,130)
Commercial bills	7,759,812	8,113,470
Advances paid to suppliers of fixed assets	56,459,179	12,931,075
Advances paid to suppliers of inventories and services	951,704	600,427
Advances paid to employees	-	-
Other receivables	9,569,638	9,154,337
Additional adjustments for depreciation	(18,731,979)	(24,725,555)
Balance at the end of the period	369,287,301	298,073,567

The receivables are collected on time.

14. CASH AND CASH EQUIVALENTS

The cash and cash equivalents at the end of the financial year, as presented in the individual statement of cash flows, can be reconciled with related items in the balance sheet, as follows:

	Period ended on September 30, 2025 (unaudited)	Period ended on December 31, 2024 (audited)
	RON	RON
Available at the bank	14,430,946	2,673,916
Bills for collection	-	-
Cash and cash equivalents	22,994	7,426
Total	14,453,940	2,681,342

ANTIBIOTICE S.A.

EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025 (all amounts are expressed in LEI ("RON"), unless otherwise specified)

The company has accounts opened with commercial banks in Romania that are part of European banking groups or with state-owned banks.

15. SHARE CAPITAL

	Balance on September 30, 2025 (unaudited)	Balance on December 31, 2024 (audited)
	RON	RON
Fully paid-up ordinary shares	67,133,804	67,133,804

The company's subscribed share capital as of December 31, 2024 is 67,133,804 lei and the nominal value of a share is 0.1000 lei/share. The company has a number of 671,338,040 shares that provide equal rights to the company's shareholders. Antibiotice S.A. has not issued shares that provide preferential rights to the shareholders. In accordance with the provisions of IAS 29 - hyperinflationary economies, the share capital was restated taking into account the inflation index communicated by the National Statistics Commission. This was applied starting with the balance determined according to GD 500/1994, from the date of contribution until 31.12.2003, the date on which it was considered that the national economy ceased to be hyperinflationary. Subsequently, the share capital increased according to the historical amounts registered with the Trade Register.

As of 31.12.2012, the company's balance sheet includes a retained earnings loss resulting from the first-time application of IAS 29 "Financial Reporting in Hyperinflationary Economies" which is proposed to be covered from the amount resulting from the application of IAS 29 "Financial Reporting in Hyperinflationary Economies" as follows:

Retained earnings loss from the first-time application of IAS 29	197,701,352
Share capital adjustments for the first time application of IFRS	197,701,352

Reserves

The reserves include the following components:

Description	Period ended on September 30, 2025 (unaudited)	Period ended on December 31, 2024 (audited)
Fixed assets revaluation reserves	244,137,422	254,696,593
Legal reserves	13,426,761	13,426,761
Deferred income tax recognized in equity	(39,153,176)	(40,751,480)
Other reserves	408,660,649	398,732,239
TOTAL	627,071,657	626,104,113

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025**
(all amounts are expressed in LEI ("RON"), unless otherwise specified)

Shareholder structure

	Balance on September 30, 2025 (unaudited)		Balance on December 31, 2024 (audited)	
	Number of shares	% ownership	Number of shares	% ownership
MINISTRY OF HEALTH	355,925,135	53.0173	355,925,135	53.0173
INFINITY CAPITAL				
INVESTMENTS S.A. *	87,475,826	13.0301	87,475,826	13.0301
Other natural and legal persons	227,937,079	33.9527	227,937,079	33.9527
Total	671,338,040	100.0000	671,338,040	100.0000

Revaluation reserve

The reconciliation between the opening and closing balance of the revaluation reserve is as follows:

	Period ended on September 30, 2025 (unaudited)	Period ended on December 31, 2024 (audited)
	RON	RON
Balance at the beginning of the period for the revaluation reserve	254,696,592	268,354,743
Balance at the beginning of the period for deferred tax related to the revaluation reserve	(40,751,480)	(42,936,784)
Transfer of revaluation reserve to retained earnings following depreciation and disposals of tangible assets, net of tax	(10,559,171)	(13,658,151)
Revaluation of tangible assets	-	-
Decrease in deferred tax related to the revaluation reserve	2,663,841	2,185,304
Deferred income tax	(1,065,537)	-
Balance at the end of the period for the revaluation reserve	244,137,422	254,696,592
Balance at the end of the period for deferred tax related to the revaluation reserve	(39,153,176)	(40,751,480)
Reconciliation of revaluation reserves	204,984,246	213,945,112

The following describes the nature and purpose of each reserve within equity:

Nature of the reserve	Description and purpose of the reserve
Fixed assets revaluation reserves	If the carrying amount of a tangible asset is increased as a result of a revaluation, then the increase must be recognized in other comprehensive income and accumulated in equity, as revaluation surplus. The revaluation reserves cannot be distributed and cannot be used to increase the share capital.
Legal reserves	According to Law 31/1990, every year at least 5% of the profit is taken to form the reserve fund, until it reaches at least one fifth of the share capital.
Other reserves	Other reserves include reserves representing tax benefits that cannot be distributed, with implications for the recalculation of corporate income tax. The difference represents reserves constituted from profits.

**EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS
FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025
(all amounts are expressed in LEI ("RON"), unless otherwise specified)**

16. TRADE AND SIMILAR DEBTS

The liabilities mainly include trade payables and other short-term financial liabilities (liabilities in relation to staff, liabilities regarding taxes and duties, liabilities regarding short-term bank loans, liabilities in relation to various creditors) which are initially recognized at fair value and subsequently recorded at amortized cost using the effective interest method.

	Balance on September 30, 2025 (unaudited)	Balance on December 31, 2024 (audited)
	RON	RON
Trade debts	77,008,345	83,501,751
Bills payable	2,795,358	2,582,237
Debts from the acquisition of fixed assets	24,261,292	44,300,365
Other current liabilities*	31,497,030	35,537,614
Advances received based on orders	1,009,253	3,311,477
Total	136,571,278	169,233,444

*Other current liabilities

	Balance on September 30, 2025 (unaudited)	Balance on December 31, 2024 (audited)
	RON	RON
Salary debts to employees and social security debts**	15,596,258	23,585,855
Unclaimed employee rights	50,803	35,708
Other creditors	3,348,363	2,911,858
Interest payable	18,894	74,601
Other taxes payable	1,088,977	424,287
Dividends payable	11,393,735	8,505,305
Total	31,497,030	35,537,614

**These debts include:

- 3,116,902 lei stand for the remuneration due to employees representing the liquidation of September 2025 paid in October 2025;
- 41,752 lei stand for the amounts withheld from staff rights according to legal regulations, related to September 2025, which will be paid to third parties;
- 162,471 lei stand for the amounts owed to employees stand for the bonuses as well as the debts to employees represented by guarantees retained by employees according to legal requirements;
- 5,050,434 lei stand for the amounts withheld according to legal requirements from the gross income of employees representing the social security contribution;
- 2,103,692 lei stand for the amounts withheld according to legal requirements from the gross income of employees representing the contribution to the social health insurance;
- 450,058 lei stand for the labor insurance contribution owed by the unit for personnel rights related to December 2024;
- 1,397,617 lei stand for the income tax withheld according to legal requirements from the gross income of employees for December 2024;
- 21,885 lei stand for settlements in the process of being clarified;
- 3,119,659 lei stand for unused vacation leaves and liabilities regarding employee profit sharing;
- 131,788 lei stand for material aid personnel due.

ANTIBIOTICE S.A.

EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025 (all amounts are expressed in LEI ("RON"), unless otherwise specified)

The claw-back tax

The claw-back tax regulated by the Emergency Ordinance no. 77/2011 on the establishment of contributions for financing certain expenses in the health sector is paid quarterly to the State Budget for **prescription medicines**, included in national health programs, with or without personal contribution, used in outpatient treatment based on medical prescription through open-circuit pharmacies, for those used in hospital treatment, borne from the National Single Health Insurance Fund and from the budget of the Ministry of Health.

Current tax and fee debts

	Period ended on September 30, 2025 (unaudited)	Period ended on December 31, 2024 (audited)
	RON	RON
VAT payable	1,691,980	-
Current profit tax	280,597	-
Clawback tax	9,500,000	10,152,471
Other special funds	284,326	157,916
Total	11,756,903	10,310,387

Debts are paid on the due date.

17. BANK LOANS

The bank loans as of December 31, 2024 and September 30, 2025 are as follows:

Financing bank	Type of financing	Granting date	Balance on December 31, 2024 (audited)	Balance on September 30, 2025 (unaudited)	In the short term on September 30, 2025 (unaudited)	In the long term on September 30, 2025 (unaudited)	Period
Banca Transilvania	Credit line – working capital	21.03.2025	33,751,804	26,224,777	26,224,777	-	12 MONTHS
Banca Transilvania	credit - supplier payments	16.05.2025	-	74,484,702	74,484,702	-	12 MONTHS
Unicredit Bank	Credit line – working capital	Initial award in 2016 renewed annually	10,548,511(*)	8,613	8,613	-	12 MONTHS
Unicredit Bank	Investment loan	03.05.2018	36,719,867(**)	29,161,672	10,922,917	18,238,755	120 MONTHS
European Investment Bank	Investment loan	26.06.2024	59,689,200	60,973,200	4,877,856	56,095,344	96 MONTHS
European Investment Bank	Investment loan	17.01.2025	-	66,054,300	-	66,054,300	96 MONTHS
TOTAL			140,709,382	256,907,264	116,518,865	140,388,399	

ANTIBIOTICE S.A.

EXPLANATORY NOTES TO INDIVIDUAL INTERIM FINANCIAL STATEMENTS FOR THE THREE-MONTH PERIOD ENDED ON SEPTEMBER 30, 2025 (all amounts are expressed in LEI ("RON"), unless otherwise specified)

18. SUBSIDIES FOR INVESTMENTS

	Period ended on September 30, 2025 (unaudited)	Period ended on December 31, 2024 (audited)
	RON	RON
On January 1	5,662,615	1,892,704
Subsidies inputs	5,320,672	4,209,120
Transferred to the statement of comprehensive income	(333,282)	(439,209)
On September 30, 2025 / December 31, 2024	10,650,005	5,662,615
Current	306,289	516,884
Fixed assets	10,343,715	5,145,731

19. CONTINGENT LIABILITIES

On September 30, 2025 and on December 31, 2024, Antibiotice S.A. has no contingent liabilities.

20. PRESENTATION OF AFFILIATED PARTIES

20.1 - Amounts due and receivable from related parties

During the period 01.01.2025 - 30.09.2025 and during the financial year ended in 2024, Antibiotice S.A. had no receivables or debts with the associated entity.

20.2 - Information regarding the transactions with affiliated parties

During the period 01.01.2025 - 30.09.2025 and during the financial year ended in 2024, Antibiotice S.A. did not carry out commercial transactions with the associated entity.

21. EVENTS AFTER THE REPORTING PERIOD

There are no significant subsequent events which are not presented in these separate interim financial statements.

22. OTHER INFORMATION

The individual interim financial statements for the 9-month period ended on September 30, 2025 are not audited.

Authorized by the Management Board on: 13.11.2025.

General Director,
Mr. Ioan NANI

Financial Director,
Mrs. Paula Luminita COMAN

STATEMENT

according to the provisions of art. 30 of the Accounting Law no. 82/1991

The Financial Statements of 30/09/2025 were prepared for:

Legal entity: Antibiotice S.A.

County: 22-Iasi

Address: City of Iasi, 1 Valea Lupului St., 707410

Trade Register number: J1191000285223

Form of ownership: 27 - Trading companies with state and local private capital
(state $\geq$ 50%)

Main activity (NACE code and class name): 2110 Manufacture of basic pharmaceutical products

Tax identification code: 1973096

The company's administrator, Ioan Nani, assumes his responsibility for the preparation of the financial statements at 30/09/2025 and confirms that:

- a) The accounting policies used in preparing the financial statements are in accordance with the applicable accounting regulations.
- b) The financial statements provide a true and fair view of the financial position, financial performance and other information relating to the activity carried out.
- c) The legal entity operates in conditions of continuity.

General Director,
Ioan Nani, Economist

CURRENT REPORT

Report date: **13.11.2025**

Name of issuing company: **Antibiotice SA**

Headquarters: **Iași, str. Valea Lupului nr. 1, zip code 707410**

<https://www.antibiotice.ro>

E-mail: **relatiicuinvestitorii@antibiotice.ro**

Telephone/fax no. : **+40232 209000 / +40232 209633**

Unique registration code in the Trade Register Office: **RO1973096**

No. in the Trade Register: **J1991000285223**

Subscribed and paid-up capital: **67,133,804.00 RON**

The regulated market trading

the securities issued: **Bucharest Stock Exchange**

Number of shares: **671,338,040**

Number of votes: **671,338,040a**

Main characteristics of the securities

issued by the company: **nominative shares, nominal value: 0.10 lei**

Notice of availability for the 2025, Q1 Report

Antibiotice Iași informs the investors that the *Q3 2025 Financial Report* is available through the *Bucharest Stock Exchange* and *Financial Surveillance Authority* as well as on our website: www.antibiotice.ro (Investors/Financial Information/Financial Reports - 2025, 9 months).

We mention that the above-mentioned report can also be obtained at our company's headquarters (Investor Relations, phone no.: 0372 065570, fax: 0372 065633, e-mail: relatiicuinvestitorii@antibiotice.ro).

Please note that the financial statements in Excel format can be found on the company's website and can be accessed using the link below:

<https://www.antibiotice.ro/en/investors/financial-information/financial-reporting/>

General Director,
Ioan NANI, Economist

Financial Director,
Paula-Luminița COMAN, Economist